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ABSTRACT

PARTICIPATION OF MOUSE DNA POLYMERASES IOTA, ETA, AND REV1 IN
TRANSLESION SYNTHESIS OF CARCINOGEN INDUCED DNA ADDUCTS
AND CARCINOGENESIS

Chad Aaron Dumstorf
March 21 , 2007

Recent advances in

undE~rstanding

the molecular mechanisms of

mutagenesis indicate that most mutations are dependent on the activity of
translesion synthesis DNA polymerases. The impact of reducing the level of
these polymerases on mutageneslis and carcinogenesis in mouse models is
poorly defined. Using knock out strategies we were able to remove polymerase
eta (pol 11), and polymerase iota (pOll) and pol eta/pol iota from the mouse and
lower REV1 in the mouse lung. This dissertation reports the changes in UVinduced carcinogenesis and mutagenesis that were observed.
Mutagenesis data in pol iota. deficient cells clearly indicate pol iota as a
mutagenic TLS polymerase in UV lesion bypass. Pol iota removal effectively
lowered the mutational frequency in both pol eta null and wild-type backgrounds.

v

Unexpectedly, after Hprt mutant screening, pol eta and pol iota deficient cells
were found to participate in UV lesion bypass in a strand-specific manner. This
suggests that not only does bypass of photoproducts occur but occurs in an
asymmetrical fashion, with preference of polymerases for leading or lagging
strand.
To examine the hypothesis that reducing the mutagenic load will reduce
the incidence of cancer, we examined how pol iota status contributes to
carcinogenesis. Despite the fact that pol iota was mutagenic in bypass of UV
induced lesions, its removal accelerated cancer formation in the pol eta null
background. The mechanisms behind this tumor suppressor function remain
elusive, but indicate pol iota may have additional cellular roles in conjunction with
its polymerase activity.
Examining the hypothesis that reducing the mutagenic load will reduce the
incidence of cancer, we developed strategies to reduce REV1 in mouse models
of lung carcinogenesis. Endogenous REV1 mRNA in the lung was effectively
lowered with the use of gene delivery of REV1 targeting ribozyme. This reduction
was found to effectively decrease the multiplicity of B[a]P-induced lung tumors.
This reduction did not affect the size or types of tumors induced suggesting
inhibition of cancer formation occurred at the initiation step. Collectively, these
data yield insight into the molecular mechanisms of mutagenesis that induce
cancer formation.
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CHAPTER I

INTRODUCTION

DNA DAMAGE
Genomic stability is central to the survival of cells, both prokaryotic and
eukaryotic. The loss of such stability is fundamental for evolution and is most
easily appreciated in single-cell organisms. It is more difficult to understand why
multicellular organisms have maintained mechanisms that result in alterations in
the primary sequence of DNA, since such alterations are thought to underlie
cancer and a wide variety of diseases associated with aging. Never the less,
these molecular pathways, collectively called DNA damage tolerance, have been
highly conserved. The chemical stability of DNA has been recognized for
decades, but the cellular DNA of living organisms is continually subjected to
many DNA damaging agents, which must be bypassed if the cell is to survive. In
this context, "bypass" refers to the completion of replication of genomes that
contain helix-distorting lesions such as those induced by the environmentally
relevant carcinogens ultraviolet (UV) radiation and benzo[a]pyrene (8[a]P). It is
now recognized that the principal mechanism underlying mutagenesis is the
direct replication of DNA that contains non-instructive bases as a result of
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adduction with these carcinogens. These agents, whether exogenous or
endogenous,

damage

DNA,

induce mutations,

and cause cancer.

This

dissertation specifically focuses on the bypass of bulky helix distorting lesions
induced by the aforementioned agents. This bypass, termed translesion
synthesis (TLS), is responsible for both error free and mutagenic bypass of these
lesions. The studies covered, in this dissertation yield new insight into the
polymerases responsible for inducing mutations after UV and B[a]P exposure
and how manipulating these polymerases effects cancer formation.

ULTRAVIOLET LIGHT
UV light is generally segregated into three varying wavelengths UV-A
(long wave UV with a -380 to -315nm wavelength), UV-B (medium wave with a
-315 to -280nm wavelength), and UV-C (short wave UV that ranges less than
280nm). Absorption of UV light produces two predominant types of DNA
damage, cyclobutane pyrimidine dimers (CPO) and 6-4 pyrimidine-pyrimidone
photoproducts (6-4PP). The structure for CPO and 6-4PP are shown in Figure
1a-b. Both of these helix-disturbing lesions can be induced by the complete
spectrum of UV light (-380nm-1 OOnm), albeit to varying extents 1.
The production of CPO's and 6-4PP's from UV-A wavelength absorption is
considered relatively minor. Despite low levels of photoproduct formation this
wavelength probably contributes to carcinogenesis. It has been postulated that
the formation of oxidative free radicals, rather than photoproduct production, is
the most damaging aspect of UV-A exposure 2 . Longer wavelengths such as
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those in the UV-A and UV-B region are long enough to pass through the ozone
and reach the earth's surface. Since UV-B also passes to the earths surface and
is energetic enough to form considerable amounts of CPO and 6-4PP
photoproducts, it is considered the most biologically significant source of UV
damage 3 . The more energetic short-wave UV-C radiation is the most damaging
to DNA, but generally does not penetrate the ozone thus preventing it from
reaching the Earth's surface. Nevertheless, the dosimetry and resulting adduct
load following UV-C exposure has been well-established after over 40 years of
use in DNA repair and mutagenesis studies. Therefore, UV-C is commonly used
in the laboratory to induce DNA photoproducts for biological studies4 . UV-C may
also be produced in occupational settings, such as welding, and may possibly
contribute to skin cancer in exposed populations 5 .
CPO form as a result of covalent linkages between adjacent pyrimidine
bases in the form of a four carbon (cyclobutane) ring, as illustrated in Figure 1a.
CPO may occur between any two pyrimidines (i.e. 5' T <> T, 5' T <>C, 5' C<> T, or
5' C<>C)6. The occurrence of the type of pyrimidine dimer formed is sequence
dependent with 5' T <>T being the most common CPO and 5' C<>C the least 7 .
Unlike CPO, 6-4PP occur primarily between 5' T <>C, 5' C<>C, and less
frequently at 5' T <> T with little formation between 5' C<> T8. This linkage, as
illustrated in Figure 1b, is a covalent bond between the C6 position of the 5'
pyrimidine and the C4 position of the 3' pyrimidine.
The frequency of photoproduct formation is greater for both CPO and 64PP at shorter wavelengths. Though it is possible that the ratio of CPO to 6-4PP

3

production varies with wavelength, it is generally considered that regardless of
wavelength, CPO occur 4 - 5 times more frequently than 6-4 photoproducts 9 ,1O.
Because the proportion and type of CPO and 6-4PP are relatively stable for UV-B
or UV-C, the decision for which wavelength to use for biological experimentation
is subject to the nature of a particular experiment. Because of this, the
experiments covered in this dissertation involve UV irradiation of both cells and
mice at different wavelengths. UV-C with a sharp 254 nm emission is used for
cell culture irradiation and UV-B with a peak at 302 nm is used for animal
irradiation.

4

1a)

HN

O~I
1b)

dR

Figure 1. Major UV light induced photoproducts 1a) Absorption of ultraviolet
(UV) light produces two predominant types of UV light induced adducts. a) T <>T
cyclobutane pyrimidine dimer (CPO) b) pyrimidine (6-4) pyrimidone photoproduct
(6-4PP).
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BENZO[A]PYRENE
Benzo[a]pyrene (B[a]P) is a natural byproduct and is ubiquitously
distributed throughout the environment through the combustion of organic matter.
B[a]P is readily absorbed via the gastrointestinal (GI) tract, lung and skin. The
compound is activated and detoxified primarily in the liver although other organs
such as the lung, skin, GI, and placenta can contribute significantly to these
processes 11 -13 . B[a]P and many other polycyclic aromatic hydrocarbons (PAH)
are activated to intermediates that covalently bind to DNA as a result of
endogenous cytochrome P450 metabolism 14. B[a]P in its unmodified form is a
hydrophobic planar shaped molecule (Figure 2a).
In order for B[a]P to bind DNA it must undergo cytochrome P450
enzymatic reactions that create a variety of phenols, dihydrodiols, and
electrophilic epoxides. While the principle mutagen is debated, it is widely
accepted that (±) anti diol-epoxides (BPDE) (Figure 2b) react at N2 -dG in DNA
(Figure 2c) to give four stereoisomers. More specifically the (+)-anti-BPDE reacts
with DNA via trans- and cis- configurations to give [+ta]- and [+ca]-B[a]P-W-dG.
Similarly (-)-anti-BPDE gives [-ta]- and [-ca]-B[a]P-W-dG adducts (Figure 2d) 15.
While all four of the steroisomers can cause mutations, principally G-T
transversions, the [+ta]-B[a]P-W-dG produces the dominant adduct

16

.

B[a]P is given to animals used in this dissertation to primarily induce
murine lung tumors. Activation to its carcinogenic potential is therefore based on
the animals' own metabolic pathways. In contrast, the human fibroblasts used in
the cell culture assays referenced throughout this dissertation lack the capacity
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for B[a]P activation. These cell culture based assays therefore require the use of
the active metabolite BPDE.

7

OH
8PU"~

BlalP
2a)

2b)

rt-d3
Ha..:cx0

I +t'a I-Blal P-N.2-dG

HO
00
~2(j3

:):)0
OH

2c)

l+la 1- BlalP-f\2 -dG
2d)

:x5b
6H

Figure 2. IIIUlstrations of the polycyclic aromatic hydrocarbon
benzo[a]pyren,e (8[a]P), its electrophilic metabolite, and major DNA
adduct. 2a) B[a]P 2b) one known metabolite benzo[a]pyrene-7,8-diol9,10-epoxide (BPDE), and 2c) DNA adduct formed on the N2 position of
guanine. 2d) Structures of the four stereoisomers of l\f-dG adducts: [+ta]-,
[+ca]-, [- ta]- and [- ca]-B[a]P-I\f-dG.
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POLYMERASE STALLING
Environmental DNA-damaging agents such as UV-light and B[a]P can
produce damage to nucleotides (lesions) which can block transcription and
replication complexes.

Inhibition of such fundamental DNA transactions may

have detrimental results, such as the induction of mutations or cell death.
Therefore, cells have evolved efficient mechanisms for the recognition of helixdistorting lesions.

Ar~Juably

the most versatile system for recognizing and

removing such lesions, including those induced by UV or B[a]P, is nucleotide
excision repair. Lesions on a base in the transcribed strand of an active gene
have a high propensity to block the RNA polymerase complex. Such polymerase
stalling induces cell-cycle arrest, and possibly apoptosis, in a p53-dependent
manner17. In addition, the stalled complex acts as damage-recognition sensor to
signal the excision repair apparatus via the Cockaynes syndrome A and B
(CSA/B) proteins.

CSA/B signals the basal transcription complex TFIIH to the

stalled polymerase, by mechanisms that are not fully understood. However, the
RNA polymerase is generally considered to "back up" in order to expose the
lesion.

The helicase activity inherent in TFIIH unwinds the DNA, allowing the

scaffolding protein XPA to gain access to the lesion and RPA to coat singlestrand DNA. Subsequent steps include endonuclease activity by XPG 3' to the
lesion and XPF-ERCC1 5' to the lesion in an ordered series of reactions.

This

results in a 26-29 base oligonucleotide gap containing the lesion. The gap is
filled in by the replicative DNA polymerase complex and sealed with a ligase.
The high fidelity of this complex ensures that this process is error-free

9

18

.

Lesions in non-transcribed regions are repaired by global genomic pathways,
which differ from transcription-coupled repair (TCR) only in the manner of lesion
recognition. It is known that CPO are initially recognized by XPE and then this
complex attracts the XPC-HHR23B complex. Lesions that distort the helix to a
greater extent, such as 6-4 PP and BPDE-induced adducts, are directly
recognized by XPC-HHR23B. The subsequent steps proceed as in TCR.
If the cell enters S-phase with residual (unrepaired) DNA damage, which
can occur if the damage is induced close to the onset of S-phase or if the cells
cannot remove the damage as a result of DNA repair defects, the DNA
polymerase may be bllocked

19

.

Current data indicate that cells may use at least

two complementary pathways to continue replication across the damage. These
pathways are collectilvely called "damage tolerance", since the damage is
tolerated rather than mmoved. These were first identified in the budding yeast S.

cere visia e, and are within the RAD6 epistasis group. Recent data have begun to
elucidate the molecular mechanisms underlying this pathway, and indicate a
remarkable conservation of these mechanisms in higher eukaryotes.

One

pathway, called "damage avoidance", copies undamaged DNA with the same
sequence as the original template. This can occur by using the sister chromatid
sequence or by "copy-choice" template switching in which the nascent strand
templated by the undamaged strand is used as the template. Both mechanisms
are recombinational in nature are considered to be error-free. An alternative
mechanism, termed translesion synthesis (TLS) uses accessory polymerases in
lieu of normal replication polymerases to bypass the damage. Unlike "damage

10

avoidance", these polymerases switch places with normal replication machinery
and continue to use the damaged strand as a template. Because the damage
remains, the bypass may result in error free or error prone incorporation of
nucleotides across thB lesion. TLS is summarized at the end of this chapter
(Figure 3).
The RAD6-dependant damage tolerance pathway is central to both of
these "damage tolerance" pathways. Though the exact mechanism cells use to
decide whether TLS or "damage avoidance" is employed remains controversial,
there are some well-characterized components. The RAD6 gene encodes the
ubiquitin conjugating Bnzyme (Ubc or E2) that is required along with RAD18
(UBL or E3) for dama<ge tolerance to occu~o. Cysteine-88, located in the RAD6
enzyme active site, is required for its ubiquitin conjugating activitl 1 . Upon
replication fork stalling, the RAD6-RAD18 complex binds to the DNA through a
chromatin associated RING finger motif22. This complex mono-ubiquitinates the
proliferating nuclear cBII antigen (PCNA) at lysine-164 (K164) which signals the
recruitment of a variety of accessory DNA pOlymerases 23 .
Current data indicate that the "damage avoidance" pathway also requires
the further poly-ubiquitination of the conjugate at lysine-63 (K63)24. This multiubiquitination allows the recruitment of MMS2, UBC13, and RAD5 which are
required for "damage avoidance" to OCCU~3.

With the stalling of replication

machinery and the poly-ubiquitination of PCNA there are at least two
mechanisms for the "damage avoidance" pathway. While both mechanisms
result in error free replication, the differences lie in where the information for non-

11

damaged sequence tHmplate arises. The first proposed mechanism uses an
allelic copy as a template. The other mechanism employs the use of the newly
25
synthesized sister strand . Regardless of the mechanism, data indicate that loss
of MMS2 ubiquitin conjugating enzyme-like protein (required for the poly-ubiquitin
chain) in S. cervisiae increases the mutagenic effect of UV light and spontaneous
mutations. Although much more controversial in higher eukaryotic cells, such
cells have homologs to the polyubiquitination machinery, and knockdown of
MMS2 results in less recombination and more mutants induced by UV. Available
data support a role for polyubiquitination in recombination-mediated damage
avoidance 26 -28 .
Current models hypothesize that mono- or polyubiquitination of PCNA is
the molecular switch that determines whether the cell will undergo damage
avoidance (polyubiquitination) or TLS (monoubiquitination)29. This process is
further complicated by studies that indicate PCNA may also be conjugated by
small ubiquitin-like modifier (SUMO) USCg at K164 30 . While poorly understood,
data indicate that the attachment of SUMO (sumoylation) to PCNA is an event
31
that occurs to recruit the helicase Srs2 to the site of damage . This recruitment
effectively prevents recombination during S phase and apparently shifts the cell
away from damage avoidance and into TLS 32 ,33. While this mechanism likely
plays an extremely important role in damage tolerance, the purpose of
sumoylation is still poorly defined. In any case, these PCNA modifications have
been shown to affect DNA damage resistance and support the notion that the

12

alternative modes of rnodification of PCNA act as molecular switches to enable
alternative functions in lesion bypass.
The second option employed by cells is termed trans lesion synthesis
(TLS). TLS also occurs at stalled replication forks, but unlike "damage
avoidance" occurs when PCNA is either monoubiquitinated or as recent data
indicates perhaps sumoylated 23 . TLS enables the cell to avoid apoptosis through
the recruitment of specialized DNA polymerases. These polymerases generally
have less stringent base pairing requirements and are able to accommodate the
lesion into their active site. These low fidelity polymerases are well adapted to
replicate across helix distorting lesion in such a way that the outcome may result
in mutagenic or error free bypass of lesion. While the exact sequence of events
that occurs in TLS is still being elucidated, much of what is currently known is
through individual polymerase and protein analysis. Three major TLS proteins
are the subject matter of the studies covered in this dissertation and a general
discussion of their history and significance in TLS is given in the following
section.
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Y-FAMIL Y POL YMERASES
Y-family

polymerases

are

a

functionally

diverse

group

of

DNA

polymerases that are characterized by their low fidelity of replication and ability to
efficiently bypass a variety of helix distorting DNA lesions. Originally named the
UmuC/DinB/Rev1/Rad30 super-family, these polymerases share similar amino
acid sequence homology to themselves and little homology to other polymerase
families

34

.

These polymerases lack proofreading capabilities and appear to

exhibit great diversity among themselves in lesion specificity, rate of nucleotide
incorporation, and extension of mismatched primer-termini. Data suggest many
of these are able to participate in lesion bypass past adducts that typically
impede normal replication machinery but the extent to which it occurs is poorly
understood 35 . These polymerases have traditionally been labeled error-prone
translesion polymerases, most likely due to their low fidelity characteristics, but
may also function in an error-free manner across these lesions 36 ,37.
TLS is generally performed by one or another of the Y-family polymerases
with one extremely important exception. DNA polymerase zeta (pol zeta/ pol l;),
which is a member of the B-family of polymerases, together with the replicative
polymerases a, 0, and £, is required for TLS to occur. Pol zeta is composed of
two subunits encoded by the REV3 and REV7 genes 38 . REV3 is the catalytic
subunit of pol zeta and results in embryonic lethality when abolished in mice 39 ,40.
Despite the embryonic lethality that occurs with REV3 knockout strategies,
insights into pol zeta function in higher eukaryotes have been gained using
antisense-mediated strategies in cell culture and in mice. Mice that express
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antisense to mREV3 endogenous RNA transcripts, which do not have completely
abolished REV3 protein, are viable, These mice also have a decreased
frequency and highly aberrant spectrum of UV-induced mutations at the
hypoxanthine-guanine phosphoribosyltransferase

(Hprt)

locus

indicating

a

fundamental role for pol zeta in TLS 39 , Additionally, these knockdown mice have
reduced levels of B cells and impaired development of high-affinity memory B
cells perhaps suggesting an additional function in somatic hypermutation 41 ,42, Pol
zeta is also capable, unlike other polymerases implicated in TLS, to efficiently
extend past DNA damaged induced lesions 43 , Since most Y-family polymerases
inefficiently incorporate nucleotides after lesion bypass, pol zeta has been
proposed to be responsible for finishing the bypass before normal replication
resumes, Additionally, human REV3 (hREV3) has been shown to be essential for
error prone translesion synthesis past UV or BPDE-induced lesions in human
fibroblasts 44 , These data collectively indicate a primary function for pol zeta in
extension past the lesion once the damage is bypassed 45 ,
Y-family TLS polymerases REV1 and pol eta are homologous in yeast and
higher eukaryotes,

In contrast, the latter cells have two additional, distinct

homologs termed pol iota and pol kappa 46 , These polymerases are capable of
accepting various DNA lesions into their active sites and are able to replicate
across helix distorting lesions that would normally impede replication machinery,
However, the cellular roles of each member of this superfamily are unknown

34

,

The studies in this dissertation were designed to examine the relative importance
of these enzymes in the bypass of structurally diverse lesions in the context of
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intact cells and to determine if members of this family are potential targets for
cancer chemoprevention.

POLYMERASE ETA
Polymerase eta (pol eta/ pol ll) is the best characterized enzyme in the Y
family and absence of the enzyme results in the skin cancer-prone xeroderma
pigmentosum variant (XP-V) syndrome. Xeroderma pigmentosum (XP) patients
are noted for the predisposition to sunlight induced skin cancer. XP is subdivided
into seven subclasses called complHmentation groups, labeled XP-A through XPG . Theses complementation groups (XP-A to XP-G) are known to exhibit a
deficiency in the rate of excision repair of UV induced DNA damage, which
contributes

to

their

cancer

predisposition.

In

addition

to

these

seven

complementation groups, there is one additional group termed XP-V. These
patients are considered variant

dUH

to exhibiting similar clinical symptoms and

cancer predisposition, but unlike thH other complementation groups have normal
excision repair after DNA damage from UV light47. Human fibroblasts derived
from the XP-V patients have a moderately increased sensitivity to the cytotoxic
effects of UV-light but are extremely hypermutable when exposed to UV, despite
having normal NER47. These CEdis also have a higher rate of transformation to
48
anchorage independence after UV .
It had been suspected for some time that the XP-V gene encoded a
protein that was involved in error-prone DNA replication, but the defective gene
product was not identified as a DNA polymerase until 1999
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.

These studies used

primer extension assays past a site-specific CPO, and isolated a homolog of the
yeast Rad30 protein in XP-V cE311 extracts 49 that was found to be capable of
bypassing T-T CPO. In addition, eiglht mutations were found in the hRad30 gene
in human XP-V cell lines, with seven resulting in severely truncated hRad30
protein

5o

.

Earlier studies also indicate that XP-V cells are less likely to

incorporate dAMP or dGMP opposite the

pyrimidine

photoproduct,

and

preferentially induce unusual CG to AT mutations arising from photoproducts in
the leading strand template 51 ,52. Coillectively these studies support the conclusion
that pol eta is a tumor suppressor, and the absence of the enzyme results in the
cancer-prone XP-V syndrome.
The mechanism of tumor suppression by pol eta appears to be its
remarkable ability to efficiently incorporate AA across TT dimers with nearly the
same efficiency and processivity as undamaged template 53 ,54. This is presumed
to result from accommodation of tlhe photoproduct within its open active site.
However, pol eta is unable to successfully complete bypass of 6-4PP
photoproducts, although it can prefEHentially incorporate a G opposite the 3'T of
the adduct 55 . Thus pol eta has evolved to specifically bypass the most common
lesion induced by UV, namely CPO between adjacent thymidine bases. It is
presumed that the hypermutability of XP-V cells after exposure to UV results
from the mutagenic bypass of the lesion by another, error-prone polymerase.
The question of the specificity of pol eta with respect to UV is
controversial.

Early studies indicated that XP-V cells were not abnormally

sensitive to BPOE 56 , but recent data indicate that mutagenic responses to BPOE
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are reduced in such cells (BurkE~ and McGregor, unpublished).

In primer

extension assays using purified Emzyme, pol eta is error prone when it bypasses
a BPDE adduct, preferentially insE~rting dAMP across from the adduct.

Such

insertion would be consistent with the observed GC to T A transversions induced
by BPDE in cells. In addition to CPD bypass, pol eta efficiently bypasses DNA
damage 57 -60 from other adducts. Pol eta has been shown to be able to efficiently
and accurately replicate through 8-oxoguanine (8-oxoG) lesions by inserting a C
across from the lesion

61

.

In vitro, such bypass has the same efficiency as that of

an undamaged G. However, the relevance of these in vitro studies with purified
enzyme to intact cells is not resolved.
The evidence implicating pol eta in the error-free TLS is convincing.
However, the polymerase or polymerases responsible for UV induced mutations
in XP-V, and by extension in wild-type cells, are unknown. The increased UVinduced mutagenesis associated with pol eta deficiency indicates that mutagenic
bypass of UV photoproducts can be catalyzed by other polymerases. Two Yfamily polymerases have been hypothesized to assume lesion bypass in the
absence of pol eta. One candidatH is pol zeta, which can bypass a thyminethymine dimer in vitro62 , and is required for a large proportion of UV mutagenesis
in both yeast and mammalian cells. Another candidate is pol iota, which
physically interacts with pol eta and co-localizes with pol eta at replication foci
following UV irradiation 63 . Chapter " examines the hypothesis that pol iota is
directly responsible for inducing mutations after UV exposure especially in pol
eta-deficient cells.
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POLYMERASE IOTA
Polymerase iota (pol t) is a Y -family polymerase encoded by the RAD30B
gene. Its shares homology to pol eta and is known to exist in many species
including drosophila and mammals, but it is not found in yeast. Pol iota has been
shown to have varying roles in species dependent in vitro lesion bypass assays.
Specifically, in vitro evidence suggE~StS that pol iota bypasses cis-syn TT dimers
in drosophilia but the human enzyme does so with lower efficiencl4 ,65. Authors
have speculated that pol iota arosl3 as a duplication of pol eta, but may have
evolved more specialized properties in evolutionary time frames.
There have been conflicting reports on the exact abilities of pol iota to
bypass various lesions in vitro. For instance, some early studies indicate pol iota
as having limited insertion across CPO, while others report complete lesion
bypass 66 . It is possible these differences may be a result of pol iota's fidelity
being template and sequence dependent 66 . While numerous primer extension
assays indicate pol iota does perform misinsertion of nucleotides across various
lesions 67 , there still is no concrete evidence suggesting a cellular role in TLS.
Two hypotheses have been promulgated regarding the outcome of putative
UV photoproduct bypass by pol iota. One suggests that bypass should be
mutagenic due to pol iota-catalyzed misinsertion of nucleotides opposite
photoproducts 67 ,68.

Pol iota is rHnowned for high rates of misinsertion of

nucleotides opposite template pyrimidines during DNA synthesis in vitro64 ,66,69.
However, a study of UV-induced mutagenesis in a shuttle vector replicated in
cultured 293T cells, in which pol iota expression was decreased using siRNA
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concluded that pol iota has no significant role in UV lesion bypass and
mutagenesis 57 . A second hypothesis is that pol iota bypass could be
antimutagenic for UV-induced C to T transition mutations. This derives from an
undisputed pol iota preference for inserting dGMP opposite template T70 leading
to the suggestion that synthesis by pol iota could be antimutagenic via insertion
of dGMP opposite lesions resulting from deamination of cystosine.

Indeed,

cytosines in dipyrimidine photoproducts readily deaminate 71 and pol iota readily
inserts dGMP opposite template uracil in cyclobutane pyrimidine dimmers

(CPD)72.
Additionally, it has been hypothesized that polymerase iota may serve
other biological roles outside of TL.S. Its pattern of nucleotide misincorporation
resembles that which occurs in somatic hypermutation 69 . Studies in pol iotadeficient mice however show normal immunoglobulin hypermutation though this
could be attributed to other low fidelity polymerases assuming its role when
absenf3. Pol iota has also been suggested to participate in a specialized form of
base excision repair (BER) in vivo. This hypothesis is supported largely because
it possesses a unique 5'- deoxyribose phosphate lyase activity and is catalytically
more active in gap filling than some types of primer extension 7o ,74.
Pol iota has been implicated in tumor suppression. The mouse Pol iota
gene is on chromosome 18 and within the Par2 (pulmonary adenoma resistance
2) locus that is a major determinant of susceptibility to urethane-induced
pulmonary adenomas. Interestingly" two strains of mice with differing lung tumor
susceptibility differ in Pol iota gene status by 25 nucleotides and 10 amino acids,
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and the two enzymes have altered substrate specificity, suggesting that pol iota
is a modifier of lung tumorigenesis 75 . More recently, the defective Pol iota allele
in the 129X1/Sv mouse strain that contains the nonsense mutation in the coding
sequence has been associated with susceptibility to urethane-induced lung
tumors 76 . These data do not indicate whether the tumor suppressor activity is
related to the polymerase function or to a separate function that is not currently
identified.

A precedent exists for the latter possibility in the case of REV1, the

polymerase activity of which is dispensable for and distinct from its role in
mutagenesis.
The function of pol iota in a cellular context has remained extremely
controversial. The experiments described in Chapter II were designed to examine
our hypothesis that pol iota is involved in the mutagenic bypass of UV
photoproducts in cells. Additionally, these studies explore the possibility that TLS
is accomplished by multiple polymerases that act preferentially to bypass
photoproducts on the leading or lagging strand template. Finally, these studies
are also used to determine pol iota participation in UV induced skin cancer in
both pol eta-proficient and pol eta-deficient mice.
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REV1

It is apparent that virtually all mutations induced by bulky DNA adducts are
dependent on the activity of DNA polymerase zeta acting in concert with another

DNA polymerase encoded by the REV1 gene 77 , which encodes the REV1 DNA
polymerase, Together, these proteins are required for the generation of 95% to
98% of UV-induced base pair substitutions in yease S ,79, In yeast the protein is
required for mutagenic TLS past adducts induced in the DNA by a variety of
mutagens SO-S3 , In vitro studies of the purified protein derived from yeast and
human sources indicate that REV1 is a deoxycytidyl transferase and incorporates
dCMP across from a non instructive abasic site S4 , Further studies indicated that
REV1 is also capable of incorporating C across from a template dG, dT, dA, and
dC with preferential insertion across from dG S5 , REV1 uses a unique mechanism
to accomplish this insertion by allowing the incoming dCTP to pair with an
arginine in the active site rather than the template base so ,

Despite this intriguing mechanism, the catalytic activity of REV1 appears
to be dispensable for TLS, It has been known for some time that the yeast rev1-1
mutant results from a mutation in REV1 that abolishes the dCMP transferaase
catalytic activity, Nevertheless, this mutant is proficient for UV mutagenesis,
These data support the conclusion that REV1 plays a structural role in TLS that
is distinct from its catalytic activitl 3 , Indeed, REV1 has an N-terminal BRCT
region and a C-terminal "interacting domain" that have variously been implicated
in protein-protein interactions and in mutagenesis s6 -s9 , REV1 has been shown to
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physically interact with the Pol zeta subunit REV? and with the other members of
the Y _famill 5,90-92 through a -100 amino acid C-terminal region in REV1 that
binds these TLS polymerases. Activity of these polymerases while bound to
REV1 was normal, as determined by in vitro primer extensions assays93. These
interactions, including the association of REV1 with replication foci, may be
mediated by ubiquitin. It has been hypothesized that the ubiquitination of PCNA
is a molecular switch that facilitates TLS94. REV1 contains ubiquitin-binding
motifs (UBMs) located at the C terminus of the protein and these motifs have
been shown to be required for association of REV1 with replication foci 95. These
data are consistent with current models that REV1 serves as a scaffolding
protein to tether error-prone polymerases to the site of stalled DNA replication
forks 96 . Whatever the mechanism, data strongly implicate REV1 in mutagenic
9Y
TLS . What remains completely unknown and untested is the role REV1 has in
carcinogensis.

Although the somatic mutation hypothesis of cancer would

predict that inhibition of the involvement of REV1 in mutagenic bypass would
lower the incidence of cancer after DNA damage, the actual consequences are
completely unknown and constitute the focus of Chapter III.
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Figure 3. Translesion synthesis. After DNA damage, polymerase 0 stalls on
the DNA lesion (not illustrated). Current data indicate that RAD6/ RAD18
monoubiquitinate PCNA which signals the recruitment of polymerase 11, I, K, and
REV1. These polymerases insert nucleotides directly across from the lesion,
most likely in a lesion or sequence dependant fashion. Polymerase ~ then, in a
semi-processive manner, extends the mispair. This forms a template-primer that
is fully extendable by polymerase 0 to continue replication 98 .
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CHAPTER II

PARTICIPATION OF MOUSE DNA POLYMERASE; IOTA IN STRAND-BIASED
MUTAGENIC BYPASS OF UV PHOTOPRODUCTS AND SUPPRESSION OF
SKIN CANCER

SUMMARY
As indicated earlier, DNA polymerase iota is a conserved Y family enzyme
that is able to bypass replication-blocking lesions in vitro. However, its role in
TLS in intact cells is unknown and remains highly controversial. We hypothesized
that this enzyme is responsible for mutagenic bypass of photoproducts, and that
this activity is responsible for the extreme hypermutability of cells that lack pol
eta. To test this, we compared UV-induced mutagenesis in primary fibroblasts
derived from wild-type mice to mice lacking functional pol iota, pol eta, or both. A
deficiency in mouse DNA polymerase eta greatly enhanced UV-induced Hprt
mutant frequencies. This enhanced UV-induced mutagenesis was strongly
diminished in cells deficient in pol iota. Pol iota deficiency also reduced UV
induced mutagenesis in wild-type cells. These data conclusively indicate that pol
iota participates in the bypass of UV photoproducts in cells. Sequence analysis of
Hprt mutants derived from each of the four genotypes indicated that the lack of
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DNA polymerase eta resulted in a dramatic increase in mutations that were
targeted by putative photoproducts in the leading strand template. Further, these
mutations were principally CG to AT transversions. This spectrum completely
recapitulates that found in human XPV cells. The lack of pol iota did not alter the
kinds of mutations in either the wild-type or pol eta-deficient background, but
there was a highly significant reduction in mutations that were targeted by
putative photoproducts in the lagging strand template. These data support the
hypothesis that pol eta is specialized for the error-free bypass of photoproducts
on the leading strand template. In the absence of this enzyme, these
photoproducts are bypassed by pol iota in a mutagenic fashion. Further, pol iota
is specialized for error-prone bypass of photoproducts in the leading strand
template. The reduced frequency of UV-induced mutants in cells lacking pol iota
would predict that these mice would have a reduced incidence of UV-induced
skin cancer. We UV irradiated and compared the UV-induced skin cancer
susceptibility of wild-type mice to mice lacking functional pol eta, pol iota, or both.
Pol iota deficiency alone had no effect on cancer susceptibility in mice with
functional pol eta. Unexpectedly, however, UV-induced skin tumors in pol iotadeficient mice developed four weeks earlier in mice concomitantly deficient in pol
eta. Collectively, these data reveal functions for pol iota in bypassing UV
photoproducts. Additionally, these data indicate that pol iota acts as a tumor
suppressor by a mechanism that is presumably distinct from is TLS functions.
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MATERIALS AND METHODS

GENERATION OF DOUBLE KNOCKOUT MICE
In an earlier studl 9 an ES cell line derived from pol t-deficient 129 mice
was used to generate pol eta knockout mice. In that stud y99 chimeric mice were
bred with B6 mice to produce F1 pol eta. heterozygotes that were then
intercrossed to generate the F2 mice. The present study began by PCRgenotyping 595 F2 mice twelve of which were pol eta +/-/ pol iota -/-. These mice
were intercrossed to generate the double homozygous mice studied here.

GENERATION AND GROWTH OF PRIMARY EAR FIBROBLASTS
Primary fibroblasts derived from ear punches were grown at 3]0 under
hypoxic conditions (2-3% O2 , 5% CO 2). These conditions were previously
reported to increase the number of population doublings and lengthen the time
before senescense of primary murine cells 100. Nitrogen gas was used to sustain
hypoxic conditions in the incubators using an oxygen control module (Biospherix,
Ltd., PROOX model 110).

Cells were maintained in MEM-a (Cambrex Bio

Science Walkersville, MD) supplemented with 10% FBS (Hyclone Laboratories,
Logan, UT), 2mM glutamine, nonessential amino acids (Mediatech, Inc. Herndon,
VA), penicillin (100 units/ml), streptomycin (100 Ilg/ml) for all assays with the
exception

of the

6-thioguanine

(6-TG) screening,

(Mediatech, Inc. Herndon, VA).
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CYTOTOXIC AND MUTAGENIC EFFECTS OF UV IRRADIATION
Fibroblasts were assayed for cytotoxic and mutagenic responses to
UV254nm radiation at early passages (6-8 population doublings) after primary
cultures were established. The UV source was a Spectroline germicidal lamp that
emits short wave UV with a peak emission at 254nm. The energy emitted by the
light was quantified using an International Light model IL 1700 radiometer and a
sensor fitted with a 254nm filter and W diffuser. The height of the light was
adjusted to deliver 0.1-0.2 J/m2/sec at the level of the cells.
A series of independent populations (1.5 x 106 cells each, plated on 150mm-diameter plates) were treated with UV254nm at fluences of 0-12 J/m 2 for pol
eta +/+ cells or 0-6 J/m 2 for pol iota -/- cells. Prior to UV exposure, the culture
medium was aspirated and the cells were washed with PBS (pH 7.4). Sufficient
dishes were used to ensure at least 1.0 x 106 surviving cells.

Each dish was

allowed 3-5 days of growth before trypsinization and passage of 1.5 x 106 cells.
After 8-9 days of post-irradiation expression, 0.5-1.0 x 106 cells were selected for
6-thioguanine (6-TG) resistance (TG r) as described below. Cytotoxic responses
to radiation were established by plating the cells at cloning density and
measuring colony forming ability. The media of cells exposed at cloning density
were replaced with fresh medium after 24 hours and 7 days post-irradiation and
stained at ~ 14 days. Colony forming ability was also determined at the time of
TG r selection by plating the cells at cloning density in nonselective medium. This
value was used to correct the observed frequency of mutants. After 14 - 20 days,

TG r clones were isolated in RNase free PBS for Hprt coding region amplification
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(described below). After colony isolation, plates were stained for missed colonies
and mutant frequency was determined, defined as the number of observed TG r
clones per 106 clonable cells (corrected for cloning efficiency). The significance of
differences in frequencies between polymerase genotypes was calculated using
the Fisher's exact test.

AMPLIFICATION AND SEQUENCING OF HPRT CDNA
Isolation of TG r clones, reverse transcriptase-PCR (RT -PCR) of the coding
region of the Hprt gene, and sequence analysis of the PCR products was done
as described below. After the 8 - 10 day expression period dishes were visually
inspected in a dark room under flashlight for apparent (macroscopic) thioguanine
resistant (TG r) colonies. Individual clones were circled before aspirating the
media washing the dish with sterile PBS (pH 7.4). A dry sterile cotton swab was
used to dry around the resistant colony before addition of 10 )11 of trypsine. A
micropipette was then used to pull the colony from the dish. Pulled colonies were
put into a sterile 50 )11 microfuge tube filled with 500 )11 sterile PBS (pH 7.4) to
dilute trypsin. The cells were pelleted by centrifugation at 15,000 x g for 10
minutes at 4°C and samples frozen at -80°C (for later amplification of the Hprt
coding region). Dishes were then stained and total colonies counted to determine
mutant frequency. Amplification of Hprt cDNA from small clones was adapted
from Yang et a/101 . The cells were either directly processed or frozen at -80°C
before cDNA preparation. While on ice the cells were lysed by adding 10 III of
Reverse Transcription (RT) lysis buffer containing1 X Superscript III RT buffer
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(Invitrogen Corp), 2 units/ill RNASE OUT (Invitrogen Corp), 25 ng/ 111 Oligo dT
(20 mer, Integrated DNA Technologies), 10 mM OTT, 500 11M dNTPs (Invitrogen
Corp), 10 units/ill Superscript III RT (Invitrogen Corp), 2.5% NP-40, H20 to 10111.
The resuspended cell pellet was transferred to a 200 111 PCR tube and incubated
for 50 minutes at 50°C. The reverse transcription (RT) reaction was terminated
by heating to 70°C for 10 minutes. Amplification was performed through two
rounds of PCR using inner and outer sets of primers. First round PCR reaction
mix contained 5 111 cDNA, 1X PCR buffer (Invitrogen Corp), 1.5 mM MgCI2
(Invitrogen Corp), 200 11M dNTPs (Invitrogen Corp), 0.2 11M outer primer A
(Integrated DNA Technologies GGC TTC CTC CTC AGA CCG CT), 0.2 11M outer
primer B (Integrated DNA Technologies ACA TCA ACA GGA CTC CTC GT), 2
units Platinum Taq polymerase (Invitrogen Corp), H20 to 50 111. Using a
Stratagene Robocycler the reaction was held at 94°C for 3 minutes, then 30
cycles of 94 °c for 30 seconds, 57°C for 30 seconds, 72°C for 1 minute, and
final extention using 72°C for 10 minutes. Second round PCR mix contained 1 111
of 1sl round product, 1X PCR buffer (Invitrogen Corp), 1.5 mM MgCI2 (Invitrogen
Corp), 200 11M dNTPs (Invitrogen Corp), 0.2 11M inner primer 3 (Integrated DNA
Technologies TTT TGC CGC GAG CCG ACC GG), 0.2 11M inner primer 4
(Integrated DNA Technologies ATT TGC AGA TTC AAC TTG CG), 2 units
Platinum Taq polymerase (Invitrogen Corp), H20 to 50 111. Second round PCR
Program using Stratagene Robocycler consisted of 94°C for 3 minutes followed
by 20 cycles of 94 °c for 30 seconds, 57°C for 30 seconds, 72°C for 1 minute
and final extension of 72 DC for 10 minutes. The final product was a.nalyzed using
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5 fll of 2 nd round product on 1% agarose prior to sequencing. The sequence of
both DNA strands was determined by automated DNA sequencing. For
sequencing dRhodamine dye terminator chemistry (Applied Biosystems) was
used along with the same inner primer 3 (Integrated DNA Technologies TTT
TGC CGC GAG CCG ACC GG), and primer 4 (Integrated DNA Technologies
ATT TGC AGA TTC AAC TTG CG) used during second round PCR.

IRRADIATION OF MICE
Eight to twelve week old mice were used for UV irradiation. All of the mice
were litter-mates and had their backs shaved once a week during the UV
irradiation period. Mice were irradiated with UV-B light. The UV source was a
bank of two UV-B lamps (Blak-Ray lamp Model XX-15M, Ultraviolet Products,
Inc., Upland, CA 91786, USA) that emit wavelengths in the 280-370 nm range,
with a peak at 302 nm. UV-B flux was measured by a UVX digital radiometer
(Model UVX-31, Ultraviolet Products, Inc., Upland, CA). UV irradiation was
terminated upon initial observation of tumor formation.

HISTOLOGICAL ANALYSIS OF MOUSE TISSUE AND SKIN TUMORS
Mice were sacrificed via CO 2 inhalation for whole body tumor and tissue analysis.
Tissue and tumors were isolated and fixed in Bouin's solution. The tissue was later
stained with haematoxylin and eosin (H&E) stain and examined.
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RESULTS

GENERATION OF MICE AND PRIMARY FIBROBLASTS
Mice with homozygous deficiencies in pol iota and pol eta were generated
by mating F2 pol eta +/-/ pol iota -/- mice. The progeny included

:~3

pol eta +1+/

pol iota -/- mice, 48 pol eta. +/-/ pol iota -/- mice, and 30 pol eta. -/-/ pol iota -/mice. The multiple progeny indicates that mice deficient in both pol eta and pol
iota develop normally and are viable. These mice were used to examine whether
pol iota has a role in response to irradiation with UV light. At the same time mice
were being irradiated to examine the susceptibility of the mice to UV lightinduced skin cancer (see below), primary fibroblasts were isolated from ear
biopsies. Primary fibroblasts were successfully derived from wild-type mice and
mice deficient in pol eta only, pol iota only and both pol eta and pol iota (Table 1).
Different cell line numbers/letters indicate the fibroblast originated from separate
mice.
Primary cells grew well in normal cell culture media (as described in the
Materials and Methods section). Growing the primary fibroblast in hypoxic
conditions lengthened the time before senescence with senescence typically
occurring around 20 population doublings and/or five cryogenic freezes.
Individual fibroblasts were examined for UV light-induced cytotoxicity and
mutagenesis.
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Mouse Strain!
Cell Line

Background

129 (83)

Pol iota +/+ Pol eta +/+

129 (35d)

Pol iota +/+ Pol eta +/+

129 (47)

Pol iota +/+ Pol eta +/+

129 (70)

Pol iota -/- Pol eta +/+

129 (69)

Pol iota -/- Pol eta +/+

129 (75d)

Pol iota +/+ Pol eta -/-

129 (34d)

Pol iota +/+ Pol eta -/-

129 (48)

Pol iota +/+ Pol eta -/-

129 (71)

Pol iota -/- Pol eta -/-

129 (73)

Pol iota -/- Pol eta -/-

Table 1. Fibroblast Cell Lines. Cell lines that were successfully derived from
wild-type mice and mice deficient in pol eta only, pol iota only, and both pol eta
and pol iota. Different cell line numbers/ letters indicate the fibroblast originated
from separate mice.
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SURVIVAL

OF

PRIMARY

MOUSE

FIBROBLASTS

FOLLOWING

UV

IRRADIATION
The influence of mouse genotype on survival of primary dermal fibroblasts
after irradiation with UV254nm was measured by colony forming ability (Figure 4).
Cells deficient in pol eta alone were moderately sensitive to killing by UV
2
irradiation at a dose 2.8 J/ m resulting in 37% survival (0 37 ) (Figure 4). In either
the pol eta deficient or pol eta proficient background, cells deficient in pol iota
were more sensitive to UV-induced cytotoxicity (Figure 4, filled squares and
diamonds). Statistical significance of the reduced survival of pol iota deficient
cells was determined by polynomial regression analysis, with the best fit provided
by cubic polynomials. This analysis revealed that the percent survival for pol eta

+/+ pol iota -/- cells was significantly lower than for pol eta +/+ pol iota +/+ cells (p

= 0.018).

This analysis also showed that the percent survival for pol eta -/- pol

iota -/- cells was significantly lower than for pol eta -/- pol iota +/+ cells (p
0.001 ).
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Figure 4. Survival of primary mouse fibroblasts following UV irradiation.
The influence of mouse genotype on survival of primary dermal fibroblasts after
irradiation with UV254nm was measured by colony forming ability, as described in
Methods. The fluence required to reduce the survival of pole eta (pol '1) +/+ pol
iota (poll) +/+ cells to 37% of the unirradiated control (D37) was 8 J/m 2 . This was
reduced to -2.8 J/m 2 in the cells derived from pol eta (pol '1) -/- pol iota (poll) +/+.
Statistical significance of the reduced survival of pol iota deficient cells was
determined by polynomial regression analysis, with the best fit provided by cubic
polynomials. This analysis revealed that the percent survival for pol eta +/+ pol
iota -/- cells was significantly lower than for pol eta +/+ pol iota +/+ cells (p =
0.018). This analysis also showed that the percent survival for pol eta -/- pol iota /- cells was significantly lower than for pol eta -/- pol iota +/+ cells (p = 0.001).
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UV LIGHT-INDUCED MUTAGENESIS AT THE HPRT LOCUS IN PRIMARY MOUSE
FIBROBLASTS
The hypoxanthine-guanine phospho ribosyl transferase (Hprt) gene is a useful
target for studying somatic mutations. This target gene is located on the X-chromosome
and encodes the Hprt protein 102. Hprt exists in low levels in all somatic tissue
constituting .005-.01 % of total mRNA 103. This protein's activity is required for the
phosphoribosylation of hypoxanthine and guanine and its enzymatic activity is part of
the salvage pathway for purine nucleic acid biosynthesis. This enzyme is also
responsible for the phosphoribosylation of purine analogs such as 8-azaguanine and 6thioguanine (6-TG) which enables them to be incorporated into DNA 104. Thus, when one
of these purine analogs is present in cell culture medium, the cells incorporate these
analogs into their DNA. This incorporation severely taxes DNA mismatch repair systems
causing cell death. If however, mutations are present in the Hprt gene, which abolish
functional enzyme, the cells do not incorporate the analog into the DNA and survive.
This purine salvage pathway provides an efficient mechanism to study induced
mutations in the Hprt gene through the selection of purine analog mutants 105. While any
of the purine analogs may be used to select for Hprt mutations, issues such as
concentration, lack of efficacy, and selection time has lead 6-TG to become the
standard in Hprt mutant selection 106. The studies covered in this dissertation utilize 6thioguanine as the purine analog for selection, the mutants of which are indicated as
thioguanine resistant (TG r).
Table 2 reports individual experiments after irradiation of cells plated on
three 150 mm-diameter dishes at a density of 104 cells/ dish. These results
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indicate the percent survival, number of mutants observed, percent survival,
number of cells selected for and mutant frequencies for three different doses.
Mutation frequency results are summarized and compared in Figure 5.
Compared to wild-type fibroblasts (Figure. 5, open diamonds), a deficiency
in mouse pol eta alone resulted in increased UV irradiation-induced mutagenesis
at the endogenous Hprt locus (Figure. 5, open squares). Interestingly, in pol etadeficient cells in which pol iota was also deficient, the mutant frequency was also
reduced (Figure. 5, closed squares), implicating pol iota in mutagenic TLS when
pol eta is absent. Even when pol eta is proficient, pol iota deficiency reduced UV
induced mutagenesis (Figure 5, compare open to closed diamonds), again
implicating mouse pol iota in bypass of UV photoproducts. The fact that the UVinduced mutant frequency in cells that are deficient in both pol eta and pol iota
(Figure 5, filled boxes) is higher than the spontaneous mutant frequency (-1 O·s)
indicates that a third polymerase performs mutagenic bypass of photoproducts.
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Iota +1+
Eta +1+

Cell
Line

UV
(J/m2)

Percent
Survival
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0
7
0
8
0
9
0
7
0
8
0
9
0
2.5
0
3

100
50
100
27
100
10
100
32
100
17
100
10
100
71
100
40
100
25
100
46
100
15
100
13

83
35d
70

Iota -1Eta +1+

69
69
75d

Iota +1+
Eta -1-

34d
48
73

Iota -1Eta -1-

73
71

a

3.8
0
2.5
0
3
0
4

TG

r

Clones
Observed
2
88
60
230
4
86
0
53
0
13
3
41
0
33
6
43
0
805
0
59

a

32
0
107

Cells
Selected
x 106

.5
4.5
.5
1
.5
1
.5
3.5
.5
1
.5
2
.5
1
.5
1
.5
2.5
.5
2
.5
1
.5
1.5

Mutants
Per 106
Clonable
Cells
12
119
255
500
17
215
0
42
0
31
26
93
0
86
33
102
0
830
0
78
0
239
0
245

Mutants Per 100
Clonable Cells
minus
Background
107:t18
245
198
42:t12
31
67:t13
86
69
830:t78
78:t22
239
245:t17

Table 2. Mutant frequencies of individual cell lines after exposure to 254nm
4
UV light. Cells were plated on three 150 mm-diameter dishes at a density of 10
cells/dish to determine mutant frequency at three varying dose, column 3. Cells
were also plated at cloning density to determine survival, column 4. Column 5 list
total mutant clones observed. Total mutant corrected for cloning efficiency (not
listed) yields the number mutants per 106 clonable cells is listed in column 5.
Column 6 list mutants per 106 cion able cells after subtracting background.
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Figure 5. Frequency of thioguanine-resistant (TG r) clones as a function
of survival after UV-irradiation. Cells were plated on three 150 mm-diameter
dishes at a density of 104 cells/cm2 to determine mutant frequency, or at cloning
density to determine survival. After attachment, plates were irradiated with UV
fluences determined from the data in Figure 4 that were estimated to give an
expected survival of 20- 40%.
The actual survival in the mutagenesis
experiments were determined as in Figure 4 and are plotted on the X-axis. The
corresponding mutant frequency at each survival is plotted on the Y-axis. Each
point represents the mean of three independent dishes at the indicated survival,
plus or minus 1 standard deviation. Mutant frequency is defined as the number
of TG r clones per million clonable cells. Each data point represents at least two
independent experiments in which 2-4 x 106 surviving cells were selected after
UV irradiation and an 8-9 day expression period. The data have been corrected
for cloning efficiency on the day of selection and the spontaneous background
mutant frequency (10' 5) has been subtracted. The arrows indicate the reduction
in mutant frequency when pol I is disrupted in the pol eta-deficient background
(larger arrow) and in the pol eta-proficient background (smaller arrow).
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SPECIFICITY OF UV-INDUCED MUTAGENESIS
To discover the types and locations of pol iota-dependent UV-induced
mutations, we sequenced independent UV-induced Hprt mutants derived from
cells of each of the four genotypes. The results are summarized in Table 3 and
presented in detail as Tables 4, 5, 6, and 7 at the end of the chapter. In all four
instances, we analyzed mutant clones for exposures that resulted in -37%
survival for that genotype (Figure 5).
To further understand the strand specificity of UV-induced mutagenesis
we determined the strand containing the dipryimidine sequence in the case of
each targeted base substitution. The proportion of mutations that arose from
putative photoproducts in either strand was multiplied by the mutant frequency
induced at the D37 for each of the four genotypes. This data is summarized as
presented in Figure 6.

WILD-TYPE CELLS
Among 36 Hprt mutant clones from wild-type cells, 31

base pair

substitutions were found (Table 3 and Table 4 at the end of the chapter).
Twenty-seven substitutions occurred at dipyrimidines, indicating that dipyrimidine
photoproducts are responsible for the majority of the UV-induced mutations.
Interestingly, 22 of the 27 substitutions are inferred to result from bypass of a
dipyrimidine photoproduct on the non-transcribed strand (Table 4).

This

represents a 4.5 fold bias in favor of mutations templated at dipyrimidines on the
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non-transcribed strand compared to the transcribed strand (Figure 6, 49 x 10-6
versus 11 x 10-6 , P <0.0001).

POL ETA-DEFICIENT CELLS
A deficiency in mouse pol eta alone resulted in an -7-fold increase in
induced mutant frequency (Table 3, compare 80 x 10-6 to 550 x 10-6 ). Sequence
analysis of UV-induced Hprt mutants in pol eta-deficient fibroblasts (Table 3 and
Table 5 at the end of the chapter) revealed increased frequencies for several
types of single base substitutions (up to 40-fold for T-A to C-G substitutions), for
tandem double base substitutions (>1 O-fold) and for exon deletions (20 fold).
The exon deletions could result from splicing abnormalities caused by mutations
in splice donor or acceptor sites. Most substitutions were at dipyrimidines (Table
5).

However, the bias in favor of mutations templated at dipyrimidines in the

nontranscribed strand was reduced from 4.5-fold in wild-type cells to 2.9 fold in
-6

-6

pol eta-deficient cells (Figure 6, 290 x 10 versus 100 x 10 ). This is consistent
with an earlier study using XP variant cells 99 . This study also shows that pol eta
is acting to preferentially bypass photoproducts in the transcribed strand. Of
notable importance is the high proportion of CG to AT tranversions, 78% (7/9) of
which arose from dipyrimidines on the transcribed strand.
In the present study of asynchronously growing mouse cells lacking pol eta,
similar frequencies and proportions of transitions and transversions were
observed following UV irradiation, and the frequency of C to T transitions was
100 x 10-6 (Table 3). The data reported here in mouse cells has some
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discrepancies with that presented in human XP varient lines 52 . In particular, in
that study when XP variant cells deficient in pol eta 52 were irradiated at the
beginning of S-phase the UV-induced substitutions included 13 transitions and
17 transversions. The calculated frequency of C to T transitions was 130 x 10-6 .
However, when the XP variant cells were irradiated in the G 1 phase to allow time
for repair before replication, transversions exceeded transitions by 11 :4, and the
calculated frequency of UV-induced C to T transitions was only 18 x 10-6 . The
differences between our study in mouse cells and human XP variant cells
irradiated in the G1 could partially be related to the relationship between repair
and replication. It could also or additionally be a result of the amount of time
available for deamination of cytosine-containing photoproducts to occur. The
later is particular noteworthy since rodent cells have a reduced level of global
nucleotide excision repair compared to human cells.

POL IOTA-DEFICIENT CELLS

Fibroblasts deficient in pol iota have UV -induced total mutant frequencies
and base substitution frequencies that are more than 2-fold lower than for wildtype cells. This decrease observed in pol iota deficient cells almost brings the
mutation frequency to background levels. Specifically, wild-type cells after UV
irradiation at

D37

6

have a mutational frequency of 80 mutants per 10- clonable

cells. Pol iota removal lowered this frequency to 32 mutants per 10-6 clonable
cells (see Table 3, compare columns 1 and 3). These differences are extremely
significant resulting in a p value of <0.0001.
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Among 18 base substitutions (Table 6, at the end of the chapter), 14 were at
dipyrimidines as listed in column three (Table 3). Notably, the dipyrimidine was
on the non-transcribed strand for 10 of these, such that the non-transcribed to
transcribed strand bias was 2.4-fold (Figure 6., 17 x 10-6 versus 7 x 10-6 , P =
0.064).

This is less than the 4.5-fold bias observed in wild-type cells. This

decrease in strand bias after UV irradiation suggests that some of the strand bias
observed in wild-type cells is a result of pol iota. Specifically pol iota is working
preferentially on the non-transcribed (leading) strand in an error prone fashion.

CELLS DEFICIENT IN BOTH POL ETA AND POL IOTA
Fibroblasts deficient in pol eta and pol iota had UV-induced mutant
frequencies (Table 3, column 4), that in comparison to cells deficient in pol eta
alone (Table 3, column 2), were reduced for all mutations. Additional reduction
was also observed for total substitutions, transitions, transversions, tandem
double base substitutions and exon deletions. These 4- to 5-fold differences are
significant with a p value of :50.05.

Among 15 substitutions at dipyrimidines,

seven are inferred to result from bypass of a lesion on the non-transcribed strand
and eight are inferred to result from bypass of a lesion on the transcribed strand
(Table 7). The fact that deficiency in both pol eta and pol iota eliminated the
6

strand bias 41 x 10-6 on the non-transcribed strand versus 46 x 10- on the
transcribed strand (Figure 6), suggests that this bias depends on both
polymerases. Also noteworthy is that the UV-induced mutant frequency of

fibroblasts deficient in both pol eta and pol iota is 120 x 10-6 (Table 3, column 4),
this is much higher than the spontaneous mutant frequency in un-irradiated cells
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(1 x 10-5 ). This is direct evidence that even in cells lack po eta and pol iota there
is an elevated mutation frequency after UV irradiation and this indicates that at
least one other polymerase performs mutagenic TLS across these lesions.
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pol '7 +1+

pol '7 -1-

pol '7 +1+

pol fJ -1-

poll +1+

poll +1+

poll -1-

poll -1-

Frequency

Frequency

Frequency

Frequency

(x 10Total mutation
frequencyb

Frameshifts

6

80 [36] C

4 (2)

Large deletions 8

4 (2)

Large insertions

2 (1)

d

(x 10-

)

6

)

550 [48] C

23 (2)
92 (8)
~11

(0)

(x 10-

6

32 [19] C

~2

(0)

2 (1)
~2

(x 10-6 )

)

(0)

120 [20] C

6 (1)
29 (5)
~6

(0)

Base substitutions
at dipyrimidine

60 (27)

390 (34)

24 (14)

23 (2)

5 (3)

sites
Tandems

~2

(0)

6 (1)

Transitions

31 (14)

180 (16)

8 (5)
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e-G ~ T-A

29 (13)

100 (9)

8 (5)

23 (4 I)

T-A ~ e-G

2 (1)

80 (7)

Transversions

29 (13)

180 (16)

10 (6)

41

e-G~A-T

4 (2)

100 (9)

2 (1)

23 (4 1)

e-G ~ G-e

~2

T-A ~ A-T

13 (6)

(0)

11

(1)

57 (5)

~2

~2

(0)

(0)

8 (5)

(7)

17 (3 1)

~6

(7)

(0)

17 (31)

T-A ~ G-e
11 (5)
11 (1)
~2 (0)
~6 (0)
Table 3. UV-induced Hprt mutation frequencies in mouse primary
fibroblasts aFrequency measurements were determined for at least 6
independent assays and using primary fibroblasts isolated from at least 2
independent mice. bMutation frequencies were determined at UV exposures
resulting in 37% cell survival. cNumbers in brackets are the number of
independent mutants sequenced (Tables 4-7). dNumbers in parentheses are the
number of independent mutations observed (Tables 4-7). 8Large deletions are
primarily deletions of exons (Tables 4-7). IThree mutants contained multiple
mutations separated by more than 100 nucleotides (see Supplemental Tables 7).
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Figure 6. Strand specificity of UV-induced mutagenesis. The strand
containing the dipryimidine sequence was determined in the case of each
targeted base substitution. The proportion of mutations that arose from putative
photoproducts in either strand was multiplied by the mutant frequency induced at
the 0 37 for each of the four genotypes as presented in Figure 5. Non-transcribed
to transcribed strand bias was lower for pol t deficient cells compared to wildtype
2.4-fold This is less than the 4.5-fold bias observed in wild-type cells. Nontranscribed strand was additional reduced from 4.5-fold in wild-type cells to 2.9fold in pol 'l-deficient cells. Double knockout eliminated strand bias suggesting
that strand bias depends on both polymerases.
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SUSCEPTIBILITY OF POL ETA AND POL IOTA DOUBLE KNOCKOUT MICE
TO UV-INDUCED SKIN CARCINOMA
To determine the susceptibility of pol eta

-f-

I pol iota

-f-

mutant mice to UV

light-induced skin carcinoma, sets of littermates were shaved on part of their
backs once a week, UV irradiated three times a week at 3.75 kJ/m 2 . These mice
were examined for skin tumors each week. Irradiation was for 20 weeks and was
discontinued when the first skin tumor was observed. Twelve pol eta -1- I pol iota

-1- mutant mice, 13 pol eta +1- I pol iota -1- mutant mice and nine pol eta +1+ I pol
iota -1- mutant mice were treated and examined. These results were then
compared to those reported earlier for wild-type and pol iota -1- mutant mice 99 .
Similar to results with wild-type mice, (Figure 7, open squares) none of the 13 pol
eta +1- I pol iota -1- mutant mice or the nine pol eta +1+ I Pol iota -1- mutant mice
developed skin tumors over the 20 week course of irradiation (data not shown).
Similar to results with the pol eta

-f-

mutant mice

99

the irradiated ears of the pol

eta -1- I pol iota -1- mutant mice became darker, curved and atrophied, while
littermate controls (e.g., pol eta +1+ I pol iota -1- mice) did not show such
abnormalities or develop skin tumors even after 30 weeks of exposure. More
importantly, UV-induced skin tumors developed in the double knockout pol eta -I-

I pol iota -1- mice starting at week 8 of irradiation. All 12 mice developed skin
tumors by week 13 (Figure 7, open circles). This data shows that time for tumor
formation in pol eta -1- I pol iota -1- is earlier than for pol eta knockout mice.
Specifically, the first UV induced skin tumors in pol eta null mice at week 12
(compared to 8 in pol eta -1- I pol iota -1-) of irradiation and the last at week 18
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(compared to 13 of pol eta -/- / pol iota -/-) (Figure 7, open diamonds),
reproduced from 99 . This pol iota dependent difference in time to skin tumor
formation is statistically significant, with low p values as determined by three
different statistical tests, a log rank test (p value

= <0.0001),

at-test (p value

=

<0.0001) and a Mann-Whitney test (p value = <0.0002). Histological analysis of
skin tumors (data not shown) revealed phenotypes in double knockout mice that
were indistinguishable from those of the pol eta null knockouts. Both developed
tumors that formed from squamous cell carcinoma in situ and advanced to
invasive carcinomas. Thus, loss of pol iota increases the susceptibility of pol eta
deficient mice to UV induced skin cancer, with no detectable change in the tumor
developmental pathway.
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Figure 7. UV light-induced skin cancer in mice. Mice were shaved once per
week and irradiated three times per week with 3.5 kJ/m 2 , for twenty weeks or
until the first skin tumor arose. Mice were inspected weekly for the development
of skin tumors. Results with 12 pol eta (pol 11) -/- / pol iota (pol I) -1- mice (open
circles) are compared with results previously reported 99 for 14 wild-type mice
(open squares) and 12 homozygous pol eta knockout mice (open diamonds),
eight of which were fol iota +1+ and four of which were pol iota +1-. We also
irradiated 13 pol eta + - / pol iota -1- mice and nine pol eta +1+ / pol iota -1- mice, none
of which developed skin tumors after 20 weeks of irradiation (not plotted). In fact,
the latter mice did not develop skin tumors after more than 41 weeks.
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DISCUSSION

This study provides new insights into the biological function of pol iota and
has several implications regarding TLS and the mutagenic and carcinogenic
effects of UV radiation.

POL IOTA PARTICIPATES IN TRANSLESION DNA SYNTHESIS
As expected based on results with human cells 52 ,107,108 and mouse
embryonic fibroblasts 99 , primary fibroblasts deficient in mouse pol eta alone are
moderately sensitive to killing by UV irradiation compared to wild-type cells
(Figure 4). Also, as expected based on results with XPV cells lacking functional
pol eta 52 , a deficiency in mouse pol iota strongly enhances UV light-induced
mutagenesis at the endogenous Hprt locus (Figure 5). This is the starting point
for the novel observation that UV mutagenesis in pol eta deficient cells is
suppressed by inactivation of pol iota (Figure 5, Table 3). This suggests that pol
iota participates in mutagenic bypass of UV photoproducts when pol eta is
deficient. The fact that pol iota deficiency also suppresses UV-induced
mutagenesis in pol eta proficient cells (Figure 5, Table 3) suggests that TLS is a
normal function of pol iota, not only a replacement function when another TLS
enzyme is missing.
The interpretation that pol iota can conduct mutagenic photoproduct bypass
in mouse cells is consistent with earlier biochemical studies suggesting that pol
68

iota contributes to enhanced UV mutagenesis in pol eta deficient XPV cells .
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Our results however differ from a recent study in which pol iota expression in
cultured 293T cells was decreased using siRNA 57 . In that study, decreased pol
iota expression had no effect on UV-induced mutagenesis. In that study
mutagenesis

was

detected

using

the

supF

gene

present

on

an

extrachromosomal shuttle vector and lead to the conclusion that that pol iota has
no significant role in UV lesion bypass and mutagenesis. Experimental
differences between that study and the ones presented here could account for
the different conclusions. These differences include the reporter (a gene in a
shuttle vector versus an endogenous chromosomal gene) used to monitor
mutagenesis and possible incomplete silencing of pol iota in 293T cells.
The extent to which pol iota contributes to bypass of UV light induced
lesions may partly depend on the type of photoproduct. Although pol eta
bypasses cis-syn thymine-thymine dimers, it cannot bypass or insert nucleotides
opposite the two distorted bases of a 6-4 photoproduct.
inserts nucleotides opposite 6-4 photoproducts.

In contrast, pol iota

Because pol iota does not

extend the resulting primer termini, other polymerases, e.g., pol kappa (pol K) or
pol zeta (pol s), have been suggested to perform that task. Thus pol iota's role
may sometimes be subservient to pol eta, perhaps explaining why pol iota's
affect on UV mutagenesis is about 2-fold lower when pol eta is present (Table 3).
Perhaps pol iota predominantly inserts nucleotides opposite photoproducts not
efficiently bypassed by pol eta. While that could occur at the replication fork, it
may also possibly occur during filling of gaps left in the DNA after the fork has
moved on 109.

However, when pol eta is missing, pol iota may assume a
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somewhat larger role in bypassing UV photoproducts, consistent with a 5-fold
mutagenic decrease when pol eta is absent (Table 3). Moreover, the details of
TLS by pol iota could differ in the presence or absence of pol eta because the
two enzymes physically interact and because pol iota localization to foci in UV
irradiated human cells is reduced in pol eta-deficient cells 110 These ideas, and
the identity of the photoproducts responsible for mutagenesis, could be tested by
combining the pol eta and pol iota defects studied here with mice defective in
global and transcription-coupled nucleotide excision repair, or with mice that
express photolyases that selectively remove cyclobutane pyrimidine dimers or 64 photoproducts 111.
The specificity of strand bias in Table 3 implies that pol iota contributes to
multiple types of UV-induced base substitutions. The pol iota-dependent
substitution specificity in Table 3 is generally consistent with the insertion
specificity of pol iota. Pol iota has been shown to preferentially misinserts dNTPs
opposite template pyrimidines 66 . The exception may be the high rate of C to T
transitions that could result from incorporation of dAMP opposite a damaged
pyrimidine (Table 3). UV-induced C to T transitions may primarily result from
"correct" insertion of dAMP opposite uracil that results from deamination of
cystosine in photoproducts 112. Based on that idea, the ability of pol iota to
preferentially insert dGMP opposite U could theoretically be antimutagenic for
cytosine deamination in general 70 and/ or during TLS of photoproducts 113 That
hypothesis is not supported by our observations. The data presented here rather
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support

that

pol

iota

promotes

rather than

suppresses

UV-dependent

mutagenesis for C to T transitions (Table 3).
POL ETA AND POL IOTA PARTICIPATE IN STRAND-SPECIFIC DNA
TRANSACTIONS
In wild-type cells or cells deficient in pol eta alone or pol iota alone, there
is a bias for UV-induced base substitutions at dipyrimidines on the nontranscribed DNA strand (Figure 6).

This bias may reflect removal of

photoproducts from the transcribed strand by transcription-coupled nucleotide
excision repair, since such repair is known to alter the mutation spectrum 107,114.
Relative to wild-type cells, the strand bias is slightly reduced when pol eta or pol
iota is deficient, and is eliminated when both enzymes are deficient (Figure 6).
This suggests that both polymerases contribute to modulating mutagenic bypass
of UV photoproducts in a strand-specific manner. The strand biases could be
related to differences in leading versus lagging strand replication enzymology
(see below), transcription, or perhaps a more prominent role in bypassing a
subset of photoproducts that remain in the non-transcribed strand for a longer
time.

STRAND BIAS FOR UV-INDUCED C-G TO A-T TRANSVERSIONS
The exception to the non-transcribed strand bias is that the majority of CG to A-T substitutions are inferred to result from lesions in the transcribed strand.
This observation in mouse cells is similar to results in XP variant cells
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.

In

human cells, a chromosomal origin of replication is located 3' to exon 1 of Hpd 15
implying that the transcribed strand of Hprt is replicated as the leading strand
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template. That interpretation is consistent with studies of replication in extracts of
XP variant cells, which generates a high proportion of C-G to A-T substitutions
arising from replication of photoproducts on the leading strand template 51 . By
extrapolation, the C-G to A-T substitutions in the present study may result from
leading strand replication, leading to the further speculation that the nontranscribed strand bias discussed above could reflect TLS during replication of
the lagging strand template. In addition to CPDs and 6-4 photoproducts, UV
irradiation also generates oxidative damage to DNA. Thus, oxidative lesions like
8-oxo-guanine may contribute to the G-C to T -A transversions observed in
irradiated fibroblasts, and possibly to the skin cancer.

However, this may be

unlikely since monobasic forms of DNA damage induced by the wavelengths
used in the present study occur at less than 1% of the frequency of dipyrimidine
photoproducts 116 . Interestingly, the CG to AT transversions on the transcribed
strand largely originate when pol eta is deficient, suggesting that they are made
by a different TLS polymerase, such as pol iota (Table 6, in pol eta deficient
cells) or perhaps pol zeta or pol kappa (Table 7, double deficient-cells).

PARTICIPATION OF AT LEAST ONE OTHER POLYMERASE IN BYPASS OF
UV PHOTOPRODUCTS
The observation that the UV-induced mutant frequency in cells deficient in
both pol eta and pol iota (Table 3), is much higher than the spontaneous mutant
frequency of un-irradiated cells indicates that at least one other polymerase
performs mutagenic TLS. One candidate is pol zeta. Notably, yeast pol zeta has
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recently been shown to efficiently bypass UV photoproducts when assisted by
accessory proteins 117. This polymerase, despite belonging to the 8-family, which
mostly contains

high

fidelity

replicative

polymerases

remarkably copies

undamaged templates with low fideli ty l18.

POL IOTA HAS A FUNCTION IN DELAYING THE ONSET OF UV LlGHTINDUCED SKIN CANCER
There are well known correlations between increased mutagenesis and
increased carcinogenesis, and there is considerable evidence to support the
hypothesis that a mutator phenotype promotes multistage carcinogenesis 119.
Thus, it was unexpected to observe that UV light-induced skin cancer is
suppressed by pol iota (Figure 7), even though pol iota appears to contribute to
mutagenic bypass of photoproducts (Figure 5 and Table 3). Several hypotheses
can be considered. It could simply be that mutagenesis at the Hprt locus in
primary fibroblasts does not reflect rate-limiting mutations in the cell types and/ or
genes most relevant to development of skin tumors in mice. Against this are
similar measurements of mutagenesis at the Hprt locus in pol eta-deficient XPV
fibroblasts that do demonstrate elevated UV-induced mutant frequencies that
correlate with elevated susceptibility to skin cancer. It could be that the function
of pol iota that suppresses skin cancer is simply to bypass lesions, regardless of
whether this is performed in an accurate or mutagenic fashion. Alternatively, pol
iota could modulate cancer susceptibility via a function other than TLS.

Recent

studies have reported that polymerases implicated in TLS also participate in
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recombination 120,121, in nucleotide excision repair 122 , and in checkpoint response
to UV irradiation 123. If pol iota were to have similar roles in the absence of pol
eta, then loss of function could increase susceptibility to skin cancer. In fact, loss
of either TLS or checkpoint control due to pol iota deficiency might logically be
anticipated to result in increased UV-induced cytotoxicity, Because the cytotoxic
effect is not drastically increased could indicate that some photoproducts are
initially tolerated and later bypassed by a different polymerase to yield delayed
mutagenesis 124,125. Another possibility is that pol iota may play an important role
in development of normal immunity, such that a pol iota deficiency would
compromise immune suppression of skin cancer and lead to increased
susceptibility. Against this possibility are reports that class switch recombination
and somatic hypermutation of immunoglobulin genes appear to be normal in 129derived strains of mice 73 ,126. Finally, it is formally possible that some cells in the
double knockout mice may retain pol iota activity.

As mentioned in the

introduction, 129 mice are homozygous for a spontaneous C to A mutation in
exon 2 that creates a nonsense codon in the Pol iota gene at Ser27, such that
the protein should be truncated 73 . Indeed, no pol iota protein was detected by
Western blotting of testis extracts of 129 mice using an antibody raised against
the COOH terminus of murine pol iota that recognizes full-length or mis-spliced
variants of pol iota 73 . However, a recent studi 27 has reported that crude extracts
of brain cells from 129/J mice (but not extracts of other 129/J cells) have the
ability to insert dGMP opposite template T in an oligonucleotide primer-template.
The authors claim that this misinsertion activity is due to pol iota, rather than any
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of the other DNA polymerases that can insert dGMP opposite T, and they further
speculate that brain cells of 129 mice contain alternatively-spliced pol iota that
retains catalytic activity.
The observation that pol iota delays onset of skin cancer in pol eta deficient
mice (Figure 7) is consistent with other studies suggesting a role for mouse pol
iota in tumor suppression. The mouse Pol iota gene is on chromosome 18 and
within the Par2 (pulmonary adenoma resistance 2) locus that is a major
determinant

of

susceptibility

to

urethane-induced

pulmonary

adenomas.

Interestingly, two strains of mice with differing lung tumor susceptibility differ in
Pol iota gene status by 25 nucleotides and 10 amino acids, and the two enzymes

have altered substrate specificity, suggesting that pol iota is a modifier of lung
tumorigenesis 128. More recently, the defective Pol iota allele in the 129X1/Sv
mouse strain that harbors the nonsense mutation in the coding sequence has
been associated with susceptibility to urethane-induced lung tumors 129.
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Table 4. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta +1+ Pol
iota +I+mice.
Strand with
Surrounding
Amino acid
affected
Mutant
Mutation
Position
a
seguence
changed
die~rimidine
Dipyrimidine Base
Substitutions
Mutations involving
cytosine

WT7

C-G ---> T-A

74

ATA C.QT AAT

Pro ---> Leu

Nontranscribed

WT15

C-G ---> T-A

74

ATA C.QT AAT

Pro ---> Leu

Nontranscribed

WT3

C-G ---> T-A

74

ATA C.QT AAT

Pro ---> Leu

Nontranscribed

WT19

C-G ---> T-A

113

ATT C.QT CAT

Pro ---> Leu

Nontranscribed

WT1

C-G ---> T-A

145

AGA.QTT GCT

Leu ---> Phe

Nontranscribed

WT18

C-G ---> T-A

145

AGAgTT GCT

Leu ---> Phe

Nontranscribed

WT512

C-G ---> T-A

145

AGAgTTGCT

Leu ---> Phe

Nontranscribed

WT412

C-G ---> T-A

151

GCT gGA GAT

Arg ---> STOP

Nontranscribed

WT4

C-G ---> T-A

209

AAG GQ.G GGC

Gly---> Glu

Transcribed

WT14

C-G ---> T-A

508

TCT gGA AGT

Arg ---> STOP

Nontranscribed

WT22

C-G ---> T-A

550

ATT gCA GAC

Pro ---> Ser

Nontranscribed

WT112

C-G ---> T-A

550

ATT gCA GAC

Pro ---> Ser

Nontranscribed

WT15

C-G ---> T-A

601

AGGQ.ATTTG

Asp ---> Asn

Transcribed

WT40

C-G ---> A-T

134

GAC AQ.G ACT

Arg ---> Met

Transcribed

WT35

C-G ---> A-T

379

ACT Q.GAAAG

Gly ---> STOP

Transcribed

WT44

T-A ---> C-G

194

GCC CIC TGT

Leu ---> Pro

Nontranscribed

WT6

T-A ---> A-T

125

CTG AIT ATG

lie ---> Asn

Nontranscribed

WT51

T-A ---> A-T

125

CTG AIT ATG

lie ---> Asn

Nontranscribed

WT7

T-A ---> A-T

125

CTG AIT ATG

lie ---> Asn

Nontranscribed

WT28

T-A ---> A-T

245

TAC AIT AAA

lie --->Asn

Nontranscribed

WT8

T-A ---> A-T

245

TAC AIT AAA

lie --->Asn

Nontranscribed

WT532

T-A ---> A-T

410

ATA AIT GAC

lie --->Asn

Nontranscribed

WT213

T-A ---> G-C

194

GCC CIC TGT

Leu ---> Arg

Nontranscribed

WT512

T-A ---> G-C

194

GCC CIC TGT

Leu ---> Arg

Nontranscribed

WT10

T-A ---> G-C

424

AAAACA ATG

Thr ---> Pro

Transcribed

WT71

T-A ---> G-C

449

CTG GIT AAG

Val--->Gly

Nontranscribed

WT510

T-A ---> G-e

449

eTG GIT AAG

Val--->Gly

Nontranscribed

Mutations involving
thymidine
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Mutant

Mutation

Position

CoG

113

Surrounding
sequencea

Amino acid
changed

Nontandem double base
substitutions
WT2

WT12

-7

ToA

CoG

-7

AoT

115

e-G

-7

T-A

113

CoG

-7

AoT

118

Nondipyrimidine base
substitutions
WT31 b

CoG

-7

AoT

157

WT43

ToA

-7

}
}

AoT

ATT CgT gAT

Pro

-7

Leu

His

-7

Asn

Pro

---1

Leu

CgT CAT §.GA

Gly

-7

STOP

GAT §.TC ATG

Val

-7

Phe

GTC ATG CCG

START

-7

Leu

Frameshifts
WT83

+T

372 - 374

ACITTA ACT

WT11

+T

655

AAAGCCIAA

Exon deletions
WT96

Exon 2-3

WT171

Exon 7

Large insertion
WT243

+67 bases

403,404

aSequences of the non-transcribed (coding) strand
bCcomplex photoproducts have been suggested to occur at ACA sequences.
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STOP

-7

Leu

Strand with
affected
dipyrimidine

Table 5. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta -/- Pol
iota +1+ mice.
Strand with
Surrounding
Amino acid
affected
Mutant
Mutation
Position
a
seguence
changed
die}'rimidine
Dipyrimidine Base
Substitutions
Mutations involving
cytosine

H6

CoG

--i

ToA

74

ATA CQT AAT

Pro

--i

Leu

Nontranscribed

H3

CoG

--i

ToA

74

ATA CQT AAT

Pro

--i

Leu

Nontranscribed

H31

CoG

--i

ToA

464

AGC CQC AAA

Pro

--i

Leu

Nontranscribed

H5

CoG

--i

ToA

464

AGC CQC AAA

Pro

--i

Leu

Nontranscribed

H29

CoG

--i

ToA

464

AGC CQC AAA

Pro

--i

Leu

Nontranscribed

H12

CoG

--i

ToA

544

TTT §AAATT

Glu

--i

Lys

Transcribed

H2

CoG

--i

ToA

551

ATT CQA GAC

Pro

--i

Leu

Nontranscribed

H15

CoG

--i

ToA

551

ATT CQA GAC

Pro

--i

Leu

Nontranscribed

H9

C'G

--i

T'A

551

ATT CQA GAC

Pro

--i

Leu

Nontranscribed

H62

CoG

--i

AoT

329

CAG TQA ACG

Ser

--i

STOP

Nontranscribed

H18

CoG -> AoT

329

CAG TQA ACG

Ser -> STOP

Nontranscribed

H16

CoG -> AoT

355

GGT§GA GAT

Gly

STOP

Transcribed

H13

CoG -) AoT

400

GTT§AAGAT

Glu -> STOP

Transcribed

H1

CoG

AoT

580

CTT §AC TAT

Asp -> Tyr

Transcribed

H17

CoG -> AoT

589

AAT§AG TAC

Glu -> STOP

Transcribed

H23

CoG -> AoT

601

AGG§ATTTG

Asp

--i

Tyr

Transcribed

H21

CoG -> AoT

606

GATTT§AAT

Leu

--i

Phe

Transcribed

H14

CoG -> AoT

634

ACT§GAAAA

Gly -> STOP

ATT QCA GAC

Pro -> Ala

H19

--i

CoG->GoC

550

--i

Transcribed
Nontranscribed

Amino acid
changed

Strand with
affected
dipyrimidine

Mutant

Mutation

Position

Surrounding
a
sequence

H23

ToA -> AoT

214

GGCIAT AAG

Tyr -> Asn

Nontranscribed

H24

ToA

--i

AoT

389

AAT GIC TTG

Val-> Asp

Nontranscribed

H71

ToA

--i

AoT

389

AAT GIC TTG

Val

Asp

Nontranscribed

H85

ToA -> AoT

437

ACTTIG CTT

Leu -> STOP

Nontranscribed

H45

ToA -> AoT

543

GGA TTIGAA

Phe

Leu

Nontranscribed

H76

ToA -> CoG

203

GTG CICAAG

Leu -> Pro

Nontranscribed

H90

ToA -> CoG

203

GTG CICAAG

Leu -> Pro

Nontranscribed

H53

ToA -> CoG

254

GCA CIG AAT

Leu -> Pro

Nontranscribed

H84

ToA -> CoG

392

GTC TIG ATT

Leu -> Ser

Nontranscribed
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--i

--i

Amino acid
changed

Strand with
affected

Mutant

Mutation

Position

Surrounding
a
seguence

H26

ToA~CoG

404

GAAGATATA

Asp

~

Gly

Transcribed

H78

ToA

~

CoG

437

ACTTIG CTT

Leu

~

Ser

Nontranscribed

H30

ToA

~

CoG

542

GGA TIT GAA

Phe

~

Ser

Nontranscribed

H2

ToA

~

GoC

655

AAA GCCIAA

STOP~

ATT CCT CAT

Pro

~

Phe

Nontranscribed

Nontranscribed

Glu

di~yrimidine

Nontranscribed

Tandem dipyrimidine
base substitutions

H81

H2O

CoG

~

ToA

112

CoG

~

ToA

113

CoG

~

ToA

112

CoG

~

ToA

113

ATT CCT CAT

Pro

~

Phe

CoG

~

AoT

617

GTTT§TGTC

Cys

~

Phe

Nondipyrimidine base
substitutions

H7

b

H22b

ToA

~

AoT

109

TTT ATT CCT

lie

H27

b

ToA

~

GoC

584

GAC TAT AAT

Tyr

~

Ser

H91

b

ToA

~

GoC

584

GAC TAT AAT

Tyr

~

Ser

Asp

~

Phe

Frameshift mutations

H99

+T

578 - 579

GCC CTT GAC

H37

-TA

520,521

GGA TAC AGG

~

Exon deletions

H25

Exon 2

H10

Exon 2

H8

Exon 2-3

H60

Exon 2-5

H68

Exon 2-7

Deletions

H11
H4

c

c

H93

1'.403-456
1'.404-448

d

~533

- 553

aSequences of the non-transcribed (coding) strand
bCcomplex photoproducts have been suggested to occur at ACA and TGT sequences.
cPresumed cryptic splice acceptor within exon 6
dpresumed cryptic splice acceptor within exon 8
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STOP

Table 6. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta
iota -/- mice.

+/+

Pol

Strand with
affected

Amino acid
changed

Pro ---> His

Nontranscribed

Gly--->Glu

Transcribed

Mutation

Position

Surrounding
a
seguence

12

CoG ---> ToA

113

ATT CgT CAT

11

CoG ---> ToA

209

AAG

15

CoG ---> ToA

325

GAT gAG TCA

Gin ---> STOP

Nontranscribed

142

CoG ---> ToA

463

AGCgCC AAA

Pro ---> Ser

Nontranscribed

162

CoG ---> ToA

544

TTT ~AAATT

Glu ---> Lys

Transcribed

132

CoG ---> AoT

634

ACT~GAAAA

Gly---> STOP

Nontranscribed

124

ToA ---> AoT

64

TTG ITTTGT

Phe ---> lie

Nontranscribed

128

ToA ---> AoT

64

TTG ITTTGT

Phe ---> lie

Nontranscribed

179

ToA ---> AoT

125

CTG AIT ATG

lie --->Asn

Nontranscribed

117

ToA ---> AoT

245

TAC AIT AAA

lie --->Asn

Nontranscribed

16

ToA ---> AoT

247

AATAAAGCA

Lys ---> STOP

Transcribed

CoG ---> ToA

171

CoG ---> ToA

172
112

Mutant

di~}'rimidine

Oipyrimidine Base
Substitutions
Mutations involving
cytosine

G~G

GGC

Mutations involving
thymidine

Tandem dipyrimidine
base substitutions

114
122

CoG ---> AoT

ToA ---> AoT

113
389

CoG ---> ToA

390

CoG --) AoT

589

CoG ---> ToA

591
599

CoG ---> ToA

112

}
}
}

Met ---> lie
AT~~GAGGC

Gly ---> Arg
Pro ---> lie

ATT CCT CAT
Pro ---> lie

191

CoG ---> ToA
CoG ---> ToA

601

AATGTC TTG

}

AAT ~A§. TAC

}

TTC A§.G §.AT
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Nontranscribed

Val---> Asp
Val---> Asp

Nontandem double base
substitutions

18

Transcribed

Glu ---> STOP
Glu ---> STOP
Arg ---> Lys
Asp ---> Asn

Nontranscribed

Mutant

Mutation

Position

Surrounding
a
sequence

Amino acid
changed

Nondipyrimidine base
substitutions
b

C-G

~

A-T

397

ATT 2TT GAA

Val

~

Phe

1161

C-G

~

A-T

482

GTTGgAAGC

Ala

~

Glu

13

Exon deletions
1412

Exon 2-3

aSequences of the non-transcribed (coding) strand
bCcomplex photoproducts have been suggested to occur at ACA sequences.
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Strand with
affected
dipyrimidine

Table 7. UV-induced mutations at the Hprt locus in primary fibroblasts derived from Pol eta -/- Pol
iota -{- mice.

Mutation

Position

C-G ---7 T-A

34

AGC§.AT GAT

Asp ---7 Asn

Transcribed

HI757

C-G ---7 T-A

325

GATQAGTCA

Gin ---7 STOP

Nontranscribed

HI7

C-G ---7 T-A

464

AGC CQCAAA

Pro ---7 Leu

Nontranscribed

HI759 b

C-G ---7 T-A

493

CTG §.TG AAA

Val---7 Met

Transcribed

HI81

C-G ---7 A-T

538

GTT §.GA TTT

Gly ---7 STOP

Transcribed

HI61

C-G ---7 A-T

606

GAT TT§. AAT

Leu ---7 Phe

Transcribed

HI759 b

C-G ---7 A-T

606

GAT TT§. AAT

Leu ---7 Phe

Transcribed

HI761

C-G ---7 A-T

606

GAT TT§. AAT

Leu ---7 Phe

Transcribed

T-A ---7 C-G

146

AGA CIlGCT

Leu ---7 Pro

Nontranscribed

T-A ---7 C-G

203

GTG CIC AAG

Leu ---7 Pro

Nontranscribed

HI10 b

T-A ---7C-G

194

GCC CICTGT

Leu ---7 Pro

Nontranscribed

HI4

T-A ---7 A-T

247

ATT AAA GCA

Lys ---7 STOP

Transcribed

T-A ---7 A-T

543

GGA TTIGAA

Phe ---7 Leu

Nontranscribed

T-A ---7 A-T

656

GCC TAA GAT

STOP ---7 Leu

Transcribed

C-G ---7 T-A

112

}

ATT CCT CAT

Pro ---7 Phe

Nontranscribed

}

AGT GTI§.GA

Val---7Val

AGT GTI§.GA

Gly ---7 STOP

Mutant

Amino acid
changed

Strand with
affected

Surrounding
a
seguence

di~yrimidine

Dipyrimidine Base
Substitutions

Mutations involving
cytosine

HI761

b

b

Mutations involving
thymidine

HI76
HI761

b

HI11
HI10

b

Tandem dipyrimidine
base substitutions

HI63

113

Tandem nondipyrimidine base
substitutions

HI86

T-A ---7 G-C

516

C-G ---7 A-T

517

64

Mutant

Amino acid
changed

Mutation

Position

Surrounding
a
sequence

C-G

-1

A-T

617

GTTTQTGTC

Cys

C-G

-1

T-A

243

GAT TAQ ATT

Tyr

109

TTT 8.TT CCT

lie

451,452

GTT AAG CAG

Nondipyrimidine base
substitutions
HI2

c

HI759
HI62

bC

c

T-A

-1

A-T

-1

-1

-1

Exon deletions
HI83

Exon 2-3

HI32

Exon3

HI114

Exon 4

HI9

Exon 5

HI82

Exon 8

a Sequences

of the nontranscribed (coding strand)
bMutants containing multiple dimer sites at greater than 150 nucleotides apart
c Ccomplex photoproducts have been suggested to occur at ACA and TGT sequences.
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Tyr

Phe

Frameshifts
HI6

Phe

Strand with
affected
dipyrimidine

CHAPTER III

REV1 INHIBITION REDUCES THE INCIDENCE OF MURINE LUNG
TUMORS

SUMMARY
REV'I is a Y-family polymerase that has catalytic and structural functions
that implicate it in translesion replication across pre-mutagenic lesions in

Saccharomyces cere visa e45 , mouse 93 and human cells 130, The studies covered
within this chapter test the hypothesis that a reduction in the mutagenic load,
through REV1 inhibition, will reduce the incidence of cancer. To test this
hypothesis, vectors that express a ribozyme inhibitory RNA against REV1 were
created, One vector was designed to target the nucleus (Rz407pU6) and the
other the cytoplasm (Rz407pN2A). These vectors were complexed with the
cationic polymer polyethylenimine (PEl) and tested for their ability to reduce
REV1 mRNA in cell culture. Of the two vectors, the nuclear vector (Rz407pU6)
clearly showed reduced levels in REV1 mRNA after transfection in NIH 3T3 cells.
To reduce REV1 in the murine lung the Rz407pU6 vector was delivered via noninvasive PElf transgene aerosol therapy. This strategy is widely employed as an
effective non-viral transgene delivery method and is noted as having low
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cytotoxicity, direct pulmonary transgene delivery, and long transgene expression.
To determine REV1 mRNA levels in the mouse lung, after PEI/Rz407pU6
delivery, laser capture microdissection (LCM) was used in conjunction with realtime RT -PCR. Isolation of bronchial epithelial cells (BEC) from the lung tissue in
conjunction with real-time RT-PCR indicated REV1 mRNA levels were reduced
by at least 50% in the bronchial epithelium.
Ribozyme-mediated REV1 inhibition was used either before or after
subjecting

A/J

mice

through

a carcinogen

(B[a]P-induced)

lung tumor

modeI 131 ,132" After monitoring the mice for an extended period of time, mice were
analyzed for tumor burden via micro-positron emission tomography (microPET)
using the common tracer, [F-18]-fluorodeoxyglucose (FOG). Mice were scanned
at 12, 16, and 20 weeks with no obvious tumor formation observed. Tumors were
known to be present in 20 week-old mice by physical dissection and visualization
of the lung. MicroPET imaging either lacked the resolution or the tumors were not
metabolically active enough, opposed to surrounding tissue, to support further
microPET scanning. MicroPET screening was therefore abandoned and tumor
burden, individual tumor size, and tumor location were elucidated via lung
dissection after experiment termination,
After -28 weeks post carcinogen injection, there was a statistically
significant (p value <.02) reduction in tumor multiplicity in animals that received
aerosolized PEI/Rz407pU6 complex before carcinogen treatment. This reduction
was observed only in animals that received Rz407pU6 24 and 48 hours before
B[a]P

injection.

Mice

receiving

the
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PEIIRz407pU6

complex

developed

approximately 3.4 tumors per lung compared to approximately 6.4 in mice
receiving 8[a]P alone.

In addition to having a lower tumor multiplicity, REV1

inhibition prevented tumor formation in 27% of the carcinogen treatment group.
Tumor size or classification was not affected by treatment. Additionally, when
REV1

reduction

occurred

-4 weeks post-carcinogen

administration,

no

statistically significant effects in tumor number, size, or mice mortality were
observed.
We deduce that the inhibition of tumor development seen with REV1
inhibition is directly related to a reduction in the total number of mutations
resulting from REV1-dependant mutagenic bypass of 8[a]P lesions. The data
presented here collectively support the use of noninvasive aerosolized PEl gene
therapy and the use of ribozyme inhibitory RNAs in the chemoprevention of lung
disease. Furthermore these studies show REV1 as having a primary function in
TLS and indicate targeting mutagenic TLS polymerases can be an effective
chemoprevention strategy to reduce the incidence of cancer.
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MATERIALS AND METHODS

RIBOZYME DESIGN AND RECOMBINANT PLASMID CONSTRUCT
Hammerhead

ribozymes

were

designed

according

to

established

structural and sequence principles, maintaining the conserved catalytic core and
variable target-specific 5'- and 3'-arms 133-135. A GUC cleavage sites at position
407 on the mouse REV1 mRNA (homologous to position 618 on the human
REV1 mRNA) was chosen based on potentially accessible loop structures of the
mouse REV1 mRNA, as modeled with the MFOLD program

136.

BLAST search

determined that the targeted sequence for mouse REV1 around the GUC
cleavage site has no homology to any other murine REV RNAs and is unique to
the mouse REV1 target gene (Figure 8). The pLNSX-based retroviral vector
pN2A-tRNA (gift of Dr. H. Kobayashi, Univ. of Tokyo, Japan) modified with a Pol
III-tRNA gene ribozyme expression cassette is used for ribozyme expression
(Figure 9). This promoter system directs the fused tRNA-ribozyme transcripts into
the cytoplasm, the natural cellular compartment for tRNAs 137-141. Alternatively,
the ribozyme was cloned into pU6+27 vector containing a human U6 snrp RNA
promoter/5'··stem-loop/3'-terminator element (gift of Dr. D. Engelke) 142.
Custom-synthesized DNA oligonucleotides coding for ribozymes were
annealed and cloned between Sac II and Mlu I sites of the expression cassette in
pN2A-tRNA and the Sal I and Xba I sites of the expression cassette in pU6+27,

generating the ribozyme clones Rz407pN2A and Rz407pU6 respectively. Thus,
the cloned ribozyme inserts are transcribed from the constitutive Pol III tRNA and
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U6 promoters. The sequences coding for ribozymes were as follows; the
underlined regions correspond to the catalytic ribozyme core; the bold and italic
regions to restriction site ends.
Rz407 pN2A upper strand:
5'GGTGCAGCCCTGATGAGTCCGTGAGGACGAAACGGCTTGGTGTA3'
Rz407 pN2A lower strand:
5' CGCGTACACCAAGCCGTTTCGTCCTCACGGACTCATCAGGGCTGCACCG

C3'
Rz407pU6 upper strand:

5' TCGACTGCAGCCCTGATGAGTCCGTGAGGACGAAACGGCTTGGTGT T 3'
Rz407pU610wer strand:

5'CTAGAACACCAAGCCGTTTCGTCCTCACGGACTCATCAGGGCTGCAG3'
The presence of ribozyme inserts in clones were confirmed by sequencing and
PCR. Large scale (16L) endotoxin free plasmid production was performed by
Bayou Biolabs, LA.
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5'
3'

A CAC CAA GCC GUCA GGC UGC A
U GUGGUU CGG CA
CCG ACG U
A
C
AUG
G
A
C=G A G U
A=U
G=C
G=C

A

3' (REV1 mRNA)
5' (Active Ribozyme)

G
G U

Figure 8. Structure of mouse REV1 ribozyme. Sequence of the target mRNA
(top sequence) and the catalytically active ribozyme (bottom sequence) are
shown. The two sequence recognition arms are shown base paired with the
mouse REV1 target, surrounding the cleavage site at base 407, marked as 0'.
The central catalytic core is invariant.
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a. tRNA-Rz cassette
+1

b. U6 cassette
5' stem-loop

3' hairpin

promoter
T5 term

Figure 9. Ribozyme expression cassettes designed to target REV1 mRNA,
a. tRNA-Rz cassette for cytoplasmic localization, showing the human tRNA Met
gene with its A- and B-box internal promoters and the Pol III terminator region.
The ribozyme-coding sequence was inserted at the 3' end upstream of the
terminator; the entire cassette was inserted into the 3'-LTR of the pN2A retroviral
vector. b. U6-Rz cassette for nuclear localization, showing the human U6
promoter, the native 5' and 3' stem-loop structures and the Pol III terminator. The
ribozyme-coding sequence was inserted between the loop elements, replacing
the native U6 RNA coding region.
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PEl-DNA FORMULATIONS
Polyethylenimine (PEl), high molecular weight (water free), was obtained
from Sigma-Aldrich (CAS9002-98-6). Stock solutions were prepared at a
concentration of 4.3 mg/mL in 3xdH 20. Experiments were performed to optimize
the charge ratio expressed as PEl nitrogen:DNA phosphorous (N:P) for the
Rz407pU6 plasmid. A ratio of 15:1 N:P results in a 1.94:1 (PEI:DNA weight) ratio
and was used for all in vivo experiments. The desired amount of DNA (2 mg,
endotoxin free) was mixed in 5 ml of 3xdH 20 per nebulization experiment. PEl
was also mixed with 5 ml 3xdH20.

The DNA was slowly added to the PEl

solution with vigorous vortexing after every 1 ml added. The solution was
incubated at room temperature for 15 minutes prior to nebulization.

PElf DNA CELL TRANSFECTIONS

In vitro assays utilized Opti-MEM@I (GIBCOTM) in lieu of H20 in PElf DNA
complex preparation. Twenty minutes before transfection 2 I1g of DNA in the
forms of either gWizTM luciferase [Aldeveron] or plasmid construct Rz407pN2A or
Rz407pU6 was complexed with PEl as described above in the PEl-DNA
4

formulations in 10011 Opti-MEM@1. NIH3T3 cells seeded at a density of 2x1 0 cm

2

in six well plates had their growth media removed and the cells were rinsed in
sterile PBS (pH 7.4). Appropriate dilutions of PElf DNA complexes was then
added to each well to allow sufficient coverage. The cells were maintained at

3rC for at least 24 hours. Opti-MEM@I transfection media was then removed
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and replaced with normal media for 24hrs before subsequent analysis with a
luminometer (PharMingen MonolighFM 3010) or real-time RT - PCR.

JET-PEIIGFP COMPLEX TRANSFECTION
jetPEITM-FluoR

is

a

tetramethyl

rhodamine-conjugated

linear

polyethylenimine derivative (excitation at 555 nm; emission at 580 nm).
jetPEITM-FluoR is useful for double labelling and colocalization experiments with
green label using confocal microscopy (ie. green fluorescent protein). We utilized
this rhodamine-conjugated PEl to deliver PCDNA3 GFP plasmid into NIH3T3
cells to visualize cellular uptake and location of PEl and GFP. NIH3T3 cells were
plated in six well dishes at 5 x 105 cells per well. After cells attached ~24 hours
the media was aspirated and cells washed with sterile PBS (pH 7.4). 4ug of
PCDNA3 Green Fluorescent Protein (GFP) plasmid was combined with
JetPEITM-FluoR (Polyplus transfections, France) at varying N:P ratios (ie 10:1,
20: 1, and 30: 1) diluted in enough Opti-MEM@I transfection media to cover wells
(~2ml). Control wells received Opti-MEM@I transfection media only, GFP alone or

JetPEITM. Transfection mixtures were allowed to saturate cells for 24 hours
before visualization on fluorescent microscope outfitted with standard optical filter
sets.
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GENERAL ANIMAL
Fourteen week old, female A/J mice were used in these studies. Mice
were obtained from Jackson Laboratories and housed within the Baxter building
II animal research resource center (RRC). The animals were kept on 12 hr
day/night cycles and fed normal chow.

IN VIVO NEBULIZATION

For exposure to nebulization procedures the mice were housed, five at a
time, in a 22x9x10cm anesthesia chamber connected to Aero-Mist nebulizer
(CIS-US Bedford, MA), (Figure 10). Normal air supplemented with 5% CO 2 at a
10 L/ min flow rate (as determined by a flow meter attached to the line connected
between the air tank and nebulizer) was used to deliver 2 mg of DNA complexed
with PEl via inhalation. Each treatment took approximately 30 minutes to
complete. The mice tolerated the treatment well with no obvious signs of stress
as determined by observing mouse behavior during nebulization.

CARCINOGENESIS PROCEDURES
Forty eight hours after first PEl treatment all mice were administered either
a single bolus dose of 100 mg/ kg of B[a]P carcinogen or cornoil alone by
intraperitioneal (IP) injection. All mice received by aerosol either, Rz407pU6/PEI
or PEl (without DNA). Animals were sacrificed -28 weeks post carcinogen
injection.
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Figure 10. Mouse nebulization chamber. For exposure to nebulization
procedures the mice were housed, five at a time, in a 22x9x10cm anesthesia
chamber connected to Aero-Mist nebulizer (blue top in picture (CIS-US Bedford,
MA)) Normal air supplemented with 5% C02 was provided at a 10 Llmin flow
rate. Flow rate was determined by a flow meter attached to the line connected
between the air tank and nebulizer (black rectangular box with knob). The
nebulizer contained all PEl/DNA complex solutions.
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HOMOGENATION

OF

WHOLE

LUNG

FOR

LUCIFERASE

AND

REV1

EXPRESSION
Whole lung protein homogenates were obtained to analyze gWizTM
luciferase [Aldeveron] expression. For detecting potential strain differences PEl
mediated transfection in Balb/c verses A/J mice, 2 mg of gWizTM luciferase
[Aldeveron] was complexed with PEl as indicated in PEl/DNA formulations
section and delivered with a single treatment to three mice. Mice were sacrificed
by overdose of ketamine/ xylazine. Mice received .5 ml of 8 mg/ ml ketamine/ 1.2
mg/ ml xylazine through IP injection. Lung were then dissected and rinsed in
sterile PBS (pH 7.4) and immersed in RLB lysis solution provided in the Renilla
Luciferase Assay System with Reporter Lysis Buffer Kit (Promega catalog#
E4030). Samples were allowed one freeze/ thaw cycle to ensure complete lysis.
Upon thawing an electric rotor/stator type tissue homogenizer (The TissueTearor) was used to emulsify the sample. Renilla Luciferase substrate (provided
in Renilla Luciferase Assay System Kit) was added to each sample and read
using a luminometer (PharMingen MonolightTM 3010). For the REV1 real-time
PCR analyses, lungs were dissected and mRNA was extracted using an
Rneasy® Mini Kit (Qiagen Cat. No. 74104). Samples were disrupted in guanidine
isothiocyanate lysis buffer (provided in the kit) and homogenized using an electric
rotor/stator type tissue homogenizer (The Tissue-Tearor). Ethanol was added to
the lysate and each sample was applied to the Rneasy® mini column before
centrifugation. RNase-Free DNase Set (Cat. No. 79254) was added to each
column to ensure complete DNA removal, as required for real-time PCR, before
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total RNA was extracted in RNase free water. RNA was stored at -80° prior to
real-time analysis.

LASER CAPTURE MICRODISSECTION (LCM)
RNA isolated from whole lung homogenates did not indicate a reduction in
the levels of REV1 following ribozyme administration as determined by real-time
RT -PCR. Data however indicates bronchial epithelial cells significantly express
PElf DNA complexes 143. To isolate these cells form the surrounding tissue we
utilized Laser Capture Microdissection (LCM) technology. To measure REV1
levels post Rz407pU6 treatment, lungs were dissected 24hrs after animals
received 2 mg of the plasmid. Animals were euthanized, lungs removed and flash
frozen in O.C.T. Compound (Tissue-Tek, Sakura, Torrence, CA) using a 2Methylbutane (Sigma-Aldrich CAS 78-78-4) bath suspended in liquid nitrogen.
The frozen lungs were immediately transported to -80°C in dry ice and sectioned
in RNase free conditions. Lung sections were stained with HistoGene™ LCM
Frozen Section Staining Kit (Arcturus, Mt. View, CA) and -3000 cells were
captured on a Arcturus Pixcell® lie Laser Capture Microdissection (LCM) System
(Arcturus, Mt. View, CA) machine using CapSure ™ HS LCM Caps (Arcturus, Mt.
View, CA). RNA was isolated using PicoPure™ RNA Isolation Kit (Arcturus, Mt.
View, CA) and stored at -80°C prior to performing real-time RT-PCR.
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QUANTITATION OF LUNG REV1 MRNA USING REAL-TIME RT-PCR
Real-time quantitative RT -PCR was performed using ABI PRISM 7900
Sequence Detection System (Applied Biosystems AB, Foster City, CA) using
TagMan Universal PCR Mix (Applied Biosystems, Foster City, CA); a gene
specific MGB TaqMan Probe (Applied Biosystems); mouse REV1 primers;
TaqMan Rodent GAPDH Control reagents (Rodent GAPDH internal control
Probe, forward and reverse primers; Applied Biosystems) The TaqMan genespecific probe and primers were designed using the ABI Prism Primer Express
Software Version 1.5 (Applied Biosystems, Foster City, CA) The sequence of the
mouse REV1 primers are as follows:
mREV1 Frt (forward) - 5'CCGGGAGTTGGACGTTCA3';
mREV1 Rrt (reverse)- 5'GCAAATCTCCACAAGTCTTAATCC3';
The sequence of the mREV1 TaqMan Probe is as follows:
6FAM-AGCTTGCATCTTCG-MG BNFQ
Relative amounts of target RNA for duplicate sample runs were quantitated
with the instrument software and normalized to the corresponding GAPDH
values. Fold change values were calculated using the comparative CT method (2·
CT) 144.
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MICRO-POSITRON EMISSION TOMOGRAPHY (MICROPET)
Micro-positron emission tomography (microPET) was used in these
studies to visualize lung tumor development in mice. The microPET scans were
performed at the James Graham Brown Cancer Center (JGBCC) utilizing a paid
service. Mice were fasted for 16 hours prior to microPET. These animals were
then transported from the Baxter II animal research resource center (RRC) to the
JGBCC where the imaging took place. Mice were scanned at 12, 16, and 20
weeks, using the common tracer, [F-1S]-fluorodeoxyglucose (FOG). Following
scans mice were given normal chow and housed at the JGBCC for 24 hours
before returning to the Baxter II animal facility.

TUMOR BURDEN/ HISTOLOGY
To determine tumor burden, lungs from sacrificed animals were placed in
Tellyesniczky's Solution (90% ethanol, 5% formalin <10%>, and 5% acetic acid)
for 24 hours followed by immersion in 70% ethanol for a minimum of 24 hours.
Individual lobes of the lungs were separately dissected and gross tumors counts
were performed on the surface of each lobe using a light box. Pathology was
performed on paraffin embedded sections stained with haematoxylin and eosin
(H&E) stain.

so

STATISTICS
Statistical analyses consisted of a negative binomial regression and
planned post hoc comparisons between individual groups for tumor multiplicity
count data. One-way ANOVA and t-tests between individual groups were used
elsewhere when appropriate. Data with a trend p value of 0.05 or less were
considered significant.
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RESULTS

OPTIMIZATION

OF

PEl-REPORTER

GENES

AND

PEI-RIBOZYME

TRANSFECTION IN NIH3T3 CELLS.
The N:P ratio (PEl nitrogen:DNA phosphorous) has a significant impact on
transfection efficiency and must be optimized. We used a reporter gene gWizTM
luciferase [Aldeveron] and the Rz407pU6 and Rz407pN2A constructs to verify
expression of plasm ids constructs, optimization of N:P (PEl nitrogen:DNA
phosphorous) ratios, and verify inhibition of REV1 in both NIH3T3 cells and the
murine lung.
The greatest expression was observed in NIH3T3 cells receiving PEI/
gWizTM luciferase (PEI/Luc) at a N:P ratio of 20: 1 illustrated (Figure 11).
However, when the same cell line was exposed to PEI-Rz407pU6 (2

~g

of 2.9 kb

plasmid) complex at varying N:P ratios (10:1, 20:1, 30:1) the largest reduction in
REV1 mRNA was observed using a 10:1 N:P ratio (Figure 12). Delivery of both
plasm ids Rz407pU6 and Rz407pN2A in NIH 3T3 cells showed no additive effect.
Rz407pN2A actually appear to inhibit REV1 reduction in these cells (Figure 13).
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Figure 11. Luciferase expression in NIH3T3 cells following PElf LUC
transfection. NIH3T3 cells seeded at a density of 2x10 4 cm 2 in six well plates
had their growth media removed and the cells were rinsed in sterile PBS (pH
7.4). Appropriate dilutions of PElf Luciferase complex was then added to each
well to allow sufficient coverage. The cells were maintained at 3rC for at least
24 hours before lysis and analysis using a luminometer. Graph illustrates
significant luciferse expression in NIH3T3 using 5-25:1 N:P ratios.
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Figure 12. Analysis of REV1 mRNA inhibition in NIH 3T3 cells by real-time
RT peR after PElf Rz407pU6 transfection. NIH3T3 cells seeded at a density of
2x10 4 cells/ cm 2 in six well plates had their growth media removed and the cells
were rinsed in sterile PBS (pH 7.4). Appropriate dilutions of PEI/ Rz407pU6
complex were added to each well. Real-time RT peR analysis occurred after 24
hours. REV1 inhibition was most significant with the Rz407pU6 plasmid using a
10: 1 ratio.

84

REV1 mRNA levels in NIH3T3 cells

1.20
1.00
0.80
0.60
0.40
0.20

0.00 '----'-_'--__--"-_--'--_ _'-------L_ _- - ' - _ " " ' - - _ - - - ' - _ - - ' - -_ _ _-'-----'----1

Figure 13. Analysis of REV1 mRNA inhibition in NIH 3T3 cells by real-time
RT peR after PElf Rz407pU6 and Rz407pN2A transfection. NIH3T3 cells
seeded at a density of 2x104 cells/ cm 2 in six well plates had their growth media
removed and the cells were rinsed in sterile PBS (pH 7.4). Appropriate dilutions
of PEI/ Rz407pU6 complex were added to each well. Real-time PCR analysis
occurred after 24 hours.
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VISUALIZATION OF JET-PEl AND GREEN FLOURESCENT PROTEIN IN
MURINE NIH3T3 CELLS.
NIH 3T3 cells were treated with jetPEITM-FluoR / PCDNA3 GFP
complexes in six well dishes. Transfection mixtures were allowed to saturate
cells for 24 hours before visualization on fluorescent microscope outfitted with
standard optical filter sets.

Control cells transfected with jetPEITM-FluoR only

showed high cellular uptake of jetPEITM-FluoR (data not shown), while GFP only
did not transfect. Cells treated with the jetPEITM-FluoR / PCDNA3 GFP complex
showed broad cellular distribution of jetPEITM-FluoR (Figure 14, red) and
expression of GFP reporter plasmid in smaller foci (Figure 14, green).
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Figure 14. Visualization of jetPEITM-FluoR and PCDNA3-GFP in NIH3T3
cells. NIH 3T3 cells were treated with jetPEITM-FluoR / PCDNA3 GFP complexes
in six well dishes. Transfection mixtures were allowed to saturate cells for 24
hours before visualization on fluorescent microscope outfitted with standard
optical filter sets. Cells treated with the jetPEITM-FluoR / PCDNA3 GFP complex
showed broad cellular distribution of jetPEITM-FluoR (red) and expression of GFP
reporter plasmid in smaller foci plasmid (green).
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OPTIMIZATION OF PEI/ LUC TRANSFECTION IN LUNG TISSUE.

In vivo delivery of luciferase reporter gene was used to detect possible
strain differences in Balb/c versus A/J mice in PEl mediated gene delivery.
PEI/Luc was administered (based on the PEI/Luc N:P ratios established in cell
culture) at a N:P ratio of 15:1. 2mg of the reporter gene gWizTM luciferase
[Aldeveron] was delivered in thirty minutes. Lungs were dissected 24-48 hours
later and analyzed for luciferase expression (Figure 15). The highest expression
occurred in Balb/c mice though there was significant expression in both strains.
Collagenase was added in an attempt to reduce the total sample homogenation
time for one sample set. The additional treatment of lungs in the homogenation
step with collagenase, adversely effected the overall detection of luciferase
(Figure 15, column 3 and 4) and was discontinued. Based on these experiments
a N:P ratio of 15:1 (1.92:1 w/w) ratio was used for all subsequent in vivo
experiments.
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Figure 15. Luciferase expression in the lung. PEI/Luc was administered at a
N:P ratio of 15: 1 using 2 mg of the reporter gene gWizTM luciferase [Aldeveron].
Graph represents relative light units (RLU)/ mg of lung protein 24-48 hours after
transfection. Columns 3 and 4 show the decrease in RLU detection as result of
the addition of collagenase before lysis.
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LASER CAPTURE MICRODISSECTION
Mice were exposed twice to two milligram aerosolized doses of ribozyme
plasmid Rz407pU6 complexed with PEl (15:1 N:P ratio) or PEl aerosol alone for
30 minutes in a whole body exposure chamber. Using laser capture microdissection it was possible to isolate only the bronchial epithelium in order to
determine the expression of REV1. Figure 16 a shows a representative lung
section as stained via Arcturus protocol before isolation. The subsequent picture
Figure 16b shows the cap as it was isolated. The remaining photo Figure 16c
shows the tissue after the cap was removed. LCM bronchial epithelium was
examined after RNA isolation from -3000 cells using real-time RT -PCR.
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16a)

16c)

16b)

Figure 16a-c. Laser Capture Microdissection of Rz404pU6 treated lungs.
Lungs were dissected from the mice and flash frozen. Frozen lungs were
immediately transported to -80 D C in dry ice and sectioned in RNase free
conditions. Lung sections were stained with HistoGene ™ LCM Frozen Section
Staining Kit (Arcturus, Mt. View, CA) and cells captured on a Arcturus Pixcell® lie
Laser Capture Microdissection (LCM) System (Arcturus, Mt. View, CA) machine
using CapSure™ HS LCM Caps (Arcturus, Mt. View, CA). RNA was isolated
using PicoPure™ RNA Isolation Kit (Arcturus, Mt. View, CA) and stored at -80 D C
prior to performing real-time RT -PCR. 16a) 10x picture before capture. 16b) 10x
picture of cells captured on cap. 16c) 10x picture of tissue after removal of
capture cells.
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REV1 EXPRESSION IN MOUSE LUNG FOLLOWING AEROSOL DELIVERY OF
PElf RZ407PU6 COMPLEXES.
LCM allowed the isolation of bronchial epithelium tissue. This tissue was
analyzed for REV1 transcript levels via real-time RT -PCR as described in the
Materials and Methods section. These mice were taken in an unbiased manner
48 hours after treatment with Rz407pU6. Data in Figure 17 summarizes 3
independent real-Time RT-PCR experiments from two mice. Column 4 is the
average of the two treated mice. The treatment of RZ407pU6 lead to an
approximate 50% decrease in REV1 transcript (Figure 17).
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Figure 17. Inhibition of REV1 in the mouse lung. Graph represents a
summary of 3 independent real-time RT-peR experiments from two mice. Last
bar is the average of the two treated mice. The treatment of RZ407pU6 lead to
an approximate 50% decrease in REV1 transcript.
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MICRO-POSITRON EMISSION TOMOGRAPHY (microPET)
The microPET scans of mice at 12, 16, and 20 weeks post-carcinogen
injection were analyzed with the microPET manufacturers software. No lung
tumors were visualized at any of the time points (12,16, or 20 weeks). During the
20 week scans, two 8[a]P treated mice developed large site of injection tumors
and had to be sacrificed. Upon visual inspection of the lungs, multiple >1 mm
tumors had arisen. MicroPET imaging was therefore determined inadequate in
detecting 8[a]P induced adenomas and was abandoned. Figure 18 illustrates a
snap shot of a scan at 16 weeks.
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Figure 18. Micro-positron emission tomography (microPET). MicroPET
scans were performed at the James Graham Brown Cancer Center (JGBCC) in
collaboration with Dr. Chin Ng. Mouse pictured above was scanned at 16 weeks
after B[a]P injection and PEI/Rz407pU6 complex inhalation using the common
tracer, [F-18]-fluorodeoxyglucose (FOG). MicroPET imaging showed no
indication of lung tumors.

95

INHIBITION OF LUNG TUMOR MULTIPLICITY AFTER AEROSOL DELIVERY
OF PEI-RIBOZYME COMPLEXES.
We tested the efficacy of aerosol delivery of PEI- Rz407pU6 in the
formation of B[a]P induced lung tumors in female A/J mice. Mice were exposed
to 2mg of Rz407pU6 plasmid or control, 48 and 24hrs before treatment with
100mg/ kg B[a]P. After -28 weeks post carcinogen the mice were sacrificed,
lungs fixed, and tumor multiplicity and size recorded. Mice receiving B[a]P alone
developed about 6.4 individual tumors per mouse (Figure 20, column 3). This
was reduced to 3.4 tumors per lung (Figure 20, column 5) in mice receiving
Rz407pU6. Statistical significance was reached using analysis that included
negative binomial regression and planned post hoc comparisons between
individual groups (p value <.02).
The female A/J mice used in these studies developed 0.5 spontaneous
tumors per mouse (Figure 20, Column 1). Mice treated only with ribozyme
developed .39 tumors per mouse (Figure 20, Column 2). The differences in
spontaneous tumor burden between mice receiving PEl/corn oil alone and mice
receiving cornoil plus Rz407pU6 did not reach statistical significance.
Treatment with PElf Rz407pU6 prevented the formation of tumors in 27%
of the mice (Table 8, column 2). There was no apparent effect on which lobe
tumors developed (Table 8). There was no increase or decrease in multiplicity or
size when the PEI/ Rz407pU6 was given post carcinogen treatment when
compared to carcinogen alone (Figure 19, compare columns 4 and 5). As
expected, there remained a significant (p <.02) difference in tumor multiplicity
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between treatment with PElf Rz407pU6 before 8[a]P administration and PElf
Rz407pU6 nebulization followed by 8[a]P. Individual tumor sizes are plotted in
Figure 20. There was no statistically significant difference between groups as
determined by one-way ANOVA and t-tests.
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Figure 19. Scatter plot of number of tumors that developed in female AlJ
mice. To determine tumor burden, lungs from sacrificed animals were placed in
Tellyesniczky's Solution for 24 hours followed by emersion in 70% ethanol for a
minimum of 24 hours. Individual lobes of the lungs were separately dissected
and gross tumors counts were performed on the surface of each lobe using a
light box. Graph represents the number of tumors per mouse for each group.
8[a]P/ Ribozyme represents 8[a]P injection before Rz407pU6 was administered
(4 weeks post-carcinogen injection). Ribozyme/ 8[a]P represents treatment with
Rz407pU6 24 and 48 hours before 8[a]P injection. Mice receiving 8[a]P alone
developed about 6.4 individual tumors per mouse (Table 20, column 3). This was
reduced to 3.4 tumors per lung (Table 20, Column 5) in mice receiving
Rz407pU6. Statistical significance (p value= .02) was reached using negative
binomial regression and planned post hoc comparisons between individual
groups.
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Figure 20. Scatter plot of individual tumor size. To determine individual tumor
size, lungs from sacrificed animals were placed in Tellyesniczky's Solution for 24
hours followed by emersion in 70% ethanol for a minimum of 24 hours. Individual
lobes of the lungs were separately dissected and gross tumors counts were
performed on the surface of each lobe using a light box. Graph represents the
individual tumor size of all mice for each group. 8[a]P/ Ribozyme represents
8[a]P injection before Rz407pU6 was administerd (4 weeks post-carcinogen).
Ribozyme/ 8[a]P represents treatment with Rz407pU6 24 and 48 hours before
8[a]P injection. There were no statistically significant differences between groups
as determined by one-way ANOVA and t-tests between individual groups.
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Table 8.

Summar~

of tumor develoement
% of
Total tumors
No. of
mice
surviving with
Left Caudal
Group
mice
tumors Lung
Lobe
Control
12
42
50%
17%
Rz407pU6
13
31
60%
20%
B[a]P
12
38%
25%
100
3Ei%
28%
B[a]p+Rz407pU6 14
100
43%
30%
Rz407pU6+B[a]p 15
73

in each lobel total tumors
Cranial
Lobe
0%
20%
17%
11%
11%

Middle
Lobe
33%
0%
16%
14%
2%

Accessory
Lobe
0%
0%
4%
11%
15%

Table 8. Summary of lung tumor development. To determine tumor
development, lungs from sacrificed animals were placed in Tellyesniczky's
Solution for 24 hours followed by emersion in 70% ethanol for a minimum of 24
hours. Individual lobes of the lungs were separately dissected and gross tumors
were measured on the surface of each lobe using a light box and ruler. Total
tumors in each lobe for all groups reflected relative lobe size. The largest lobe is
the left lung and contained the majority of tumors for each group. The caudal
lobe second largest lobe and contained fewer tumors compared to the left lung
but more than the remaining lobes. Relative tumor numbers in remaining lobes
(cranial, middle, and accessory) were minimal.
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TUMOR HISTOLOGY
Tumors from each treatment group were dissected from mice in each
treatment group. Tumors were paraffin embedded and serial sectioned. Serial
sections were treated with haematoxylin and eosin (H&E) stain. Sections were
analyzed under a 10x microscope for differences in tumor histology. Mice in all
five groups showed hyperplasia (Figure 21), and homogeneous spherical
masses (Figure 21) that mayor may not have compressed surrounding lung
parenchyma, classified by A. Bennett Jenson, M.D. (Professor, Laboratory of
Vaccinology, James Graham Brown Cancer Center) as adenoma (Figure 22).
There was no histological evidence of metastasis (Figure 23).
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Figure 21. Hyperplasia! small adenoma formation in the murine lung. Lungs
from sacrificed animals were placed in Tellyesniczky's Solution for 24 hours
followed by emersion in 70% ethanol for a minimum of 24 hours. Lungs were
paraffin embedded and sectioned at 8 j..lm. Sections were stained with
haematoxylin and eosin (H&E) stain and analyzed on a microscope fitted with a
camera. Tumors from all groups exhibited the same morphology. Pictured above
is severe hyperplasia/ small adenoma formation as viewed at 10x.
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Figure 22. Adenoma formation in the murine lung. Lungs from sacrificed
animals were placed in Tellyesniczky's Solution for 24 hours followed by
emersion in 70% ethanol for a minimum of 24 hours. Lungs were paraffin
embedded and sectioned at 811m. Sections were stained with haematoxylin and
eosin (H&E) stain and analyzed on a microscope fitted with a camera. Tumors
from all groups exhibited the same morphology. Pictured above is an adenoma
as viewed at 1Ox.

103

Figure 23. Massive adenoma formation in the murine lung.. Lungs from
sacrificed animals were placed in Tellyesniczky's Solution for 24 hours followed
by emersion in 70% ethanol for a minimum of 24 hours. Lungs were paraffin
embedded and sectioned at 811m. Sections were stained with haematoxylin and
eosin (H&E) stain and analyzed on a microscope fitted with a camera. Tumors
from all groups exhibited the same morphology. Pictured above is a massive
adenoma as viewed at 10x.
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DISCUSSION
REV1 is an integral component of the lesion bypass machinery required
for bypass of replication blocking lesions. The metabolism of ubiquitous
environmental carcinogen B[a]P (Figure 2a) leads to many DNA reactive
intermediates that form such helix perturbing lesions.
Of particular historical importance, is the presumable ultimate carcinogen

(±)- 7f3, 80- dihydroxy 90, 100 -epoxy- 7, 8, 9, 10 tetrehyrobenzo[o]pyrene
(BPDE) which is implicated as the primary metabolite responsible for the majority
of mutations induced by TLS 145 (Figure 2b).The specific effect of targeting certain
TLS polymerases, including REV1, to reduce error prone bypass of lesions such
as that produced by B[a]P, is currently a topic of great research interest.
We hypothesize that by selectively inhibiting REV1 in the murine lung we
would reduce the formation of mutations resulting from B[a]P exposure. This
would effectively inhibit or reduce the initiation phase of carcinogenesis leading
to tumor development. Although knock out mice exist for REV1, the genotype
results in strain-specific effects on embryonic lethality. Survivable strains exhibit
transiently reduced weight with no other obvious abnormalities. These data
suggest that REV1 may function in a strain-dependant fashion in regards to
endogenous DNA damage 146. It currently unknown is unknown if REV1 has
additional functions in addition to its role in TLS. Based on the similarity between
data derived from yeast and higher eukaryotes, we hypothesized REV1 reduction
would inhibit mutagenesis and effectively be observable as a reduction in tumor
formation.
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GENE DELIVERY VIA PElfDNA AEROSOL INHALATION
Polyethylenimine (PEl) mediate gene therapy is an attractive means to
deliver a variety of transgene products to the lung 147,148. One major use of the
cationic polymer PEl is to complex it with DNA and aerosolizing the mixture to
deliver transgenes to the lung 149. PEl gene delivery is noted for not inducing
many cellular protective responses 150,151 that are seen with transgenes delivered
via viruses. PEl holds therapeutic promise in many pulmonary diseases that are
sensitive to exogenous particles and viruses. One important consideration
supporting PEl gene therapy in carcinogen-induced mouse models is that it does
not appear to be inflammatory to the murine lung 152,153. This feature is noteworthy
since inflammation promotion using BHT has been shown to increase both tumor
multiplicity and size in B[a]P induced tumors 154. PEl based gene delivery to the
lung has been shown to be successful in multiple animal models of human
disease and recently used to re-establishing p53 status and eradicating
metastasis of lung cancers in miceI55-158. Because of these studies, the use of
non-viral gene delivery is currently gaining promise in the fields of gene
therap/59 and was used in these studies to aid in the delivery of the REV1
targeting ribozyme plasmid Rz406Pu6.
We utilized the whole body exposure approach to deliver aerosolized PElf
DNA complexes to the murine lung. This exposure method remains a fast reliable
method to deliver and sustain transgene expression in the lung 160. REV1 levels
are cell-cycle dependant and speculate that REV1 inhibition through PEl delivery
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would be present weeks after inhalation 161. We found significant in vivo and in
vitro luciferase expression with PEI/luc 48 hours after treatment using the whole
animal approach with varying N:P ratios (Figure 11). The ratio of N:P is critical
and has a significant effect on transfection efficiency and must be optimized.
While the importance of N:P optimization to get transgenes into the cytoplasm
cannot be understated, it is notable that the plasmid compaction of DNA rather
than the N:P ratio is primarily responsible for transgene trafficking to the
nucleus 162. Significant expression using PEI/ luc in vitro occurred when Llsing a
range from 15:1 to 25:1 N:P ratio (Figure 11). When the same techniques were
applied in vivo with Rz107pU6 a ratio of 10: 1 was optimal (Figure 15). Based on
these differences a 15: 1 ratio was used for nubilization experiments and was
found to be effective. Our studies confirm PEl/DNA treatment was well tolerated
in the mouse and is not cytotoxic at the dose and exposure time uSBd cell
culture.
Initial experiments (data not shown), using electroporation, indicated both
Rz407pU6 and Rz407pN2A as very effective antiREV1 constructs, consistently
lowering transcript up to

~80%

in vitro. However when complexed with PEl

transfected into NIH 3T3 cells, Rz407pU6 and not Rz407pN2A was found to
reduce REV1 mRNA transcript (Figure 13). Rz407pN2A did not lower REV1
mRNA transcript (Figure 13). Rz407pN2A is a much larger plasmid (10.1 kb)
compared to Rz407pU6 (2.9 kb) perhaps explaining lack of REV1 inhibition and
its use in subsequent experiments was discontinued.
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REV1 INHIBITION IN THE MURINE LUNG
To determine reduction of REV1 mRNA in the murine lung we treated
mice with aerosolized PEIIRz407pU6 and analyzed whole lung homogenate for
REV1 expression via real-time PCR. Not surprisingly, due to the vast size and
diverse cell types, we observed no reduction in REV1 when analyzing total lung
mRNA. We demeaned this methodology inappropriate since PEl has been
shown to mediate significant expression of plasm ids across certain regions but
not necessarily the entire lung. However using LCM we were able to obtain cells
from the bronchial epithelium and analyze REV1 (Figures 16 and 17). This tissue
has been reported to not only significantly express plasmids delivered with
aerosolized PEl/DNA but has also been elucidated as the region harboring
bronchioalveolar stem cells (BASC) responsible for adenocarcinomas 143,163. The
studies here report here a reduction in REV1 mRNA transcript by 50%, using 4
~g

of Rz407pU6 delivered over 2 x 30min exposures (Figure 17). Together these

data support the use of PEI/ DNA based aerosol therapy as a safe and effective
method to deliver genes to bronchial epithelium. The reduction in REV1 mRNA
after Rz407pU6 transgene expression in the lung also supports the use of
hammerhead ribozymes as an effective method to consistently knockdown
REV1.

MICRO-POSITRON EMISSION TOMOGRAPHY (MICROPET)
Mice were scanned at 12, 16, and 20 weeks, using the common tracer, [F18]-fluorodeoxyglucose

(FOG).

Scans
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were

analyzed

with

micro

PET

manufacturers software (Figure 18). Unfortunately, no tumors were visible at any
of the time points. The most logical reason as to why lung tumors not were
visualized may be explained by either lack of resolution in the microPET pet
imaging system or lack of FOG uptake by the tumors. While the microPet
imaging personnel indicated that tumors approximately 0.8mm in diameter are
visible by microPET, the actual uptake of FOG by the tumor and surrounding
tissue may impact this resolution. The background levels of FOG in the lung
appeared to be relatively minor. Thus, either the resolution of microPET is less
than indicated or the tumors in the lung absorbed FOG at approximately the
same levels as the surrounding tissue.

REV1 REDUCTION DECREASES TUMOR MULTIPLICITY IN THE MURINE
LUNG
Effects of targeting certain translesion synthesis polymerases to inhibit
cancer formation remains unclear, particularly as shown in Chapter II with the
inhibition of pol iota 164. TLS however is recognized as an important mechanism of
action in the formation of mutations that eventually lead to tumor development

164

.

This hypothesis of inhibiting cancer by lowering the cells ability to erroneously
bypass DNA lesions is supported in these studies.
We report here that the use of plasmid encoding a ribozyme inhibitory
RNA (Rz407pU6) complexed with PEl and delivered to the lung before B[a]P
injection decreased lung tumor multiplicity from an average of 6.4 tumors/ mouse
to 3.7 tumors/ mouse (p value=.02) (Figure 19). There was also a reduction in the
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total number of mice that developed tumors from 100% to 73% (Table 8). Our
data suggests tumor inhibition by REV1 is primarily due to the reduction in
mutations formed through the TLS pathway. Thus, tumor inhibition by these
mechanisms is chemopreventive and requires the therapy to be initiated before
DNA adducts are replicated. These data presented here are consistent with
inhibition of initiation rather than a delay in progression. This conclusion is
supported by observations that there were no significant differences in tumor
size, the tumors were histologically similar (Figures 21-23), and 4 of 15 surviving
mice did not develop tumors (Table 8).
The question remained what effect, if any, on tumor development would
be observed when this REV1 inhibition occurred after the majority of adducts
were cleared. To address this we included one treatment group given Rz407pU6
-4weeks post carcinogen. As expected, there were no differences in mouse
mortality or tumor development and morphology.

These data suggest

noninvasive REV1 inhibition may still be used in tissue previously exposed to a
carcinogen with no ill effects and support REV1 inhibition as a useful strategy in
the chemoprevention of lung cancer.

110

TUMOR HISTOLOGY
Tumors from each treatment group were dissected from mice in each
treatment. Tumors were paraffin embedded and serial sectioned. Serial sections
were treated with haematoxylin and eosin (H&E) stain. Sections were analyzed
under a 10x microscope for differences in tumor morphology. Mice in all five
groups showed hyperplasia occurring around the bronchial epithelium (Figure
21). Homogeneous spherical masses were also observed in all groups and these
masses mayor may not have compressed surrounding lung parenchyma,
classified as adenoma (Figure 22). Additionally, extremely large adenomas with
no apparent loss of border or metastasis were observed in all groups (Figure 23).
These results indicated that Rz406pU6 had no observable effects the types of
tumors formed and suggest that inhibition occurred during the initiation phase of
carcinogenesis.
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CHAPTER IV

DISCUSSION

The data presented in this dissertation provide insights into the
mechanisms used by higher eukaryotic cells to complete the replication of
genomes that enter S-phase with residual, unrepaired DNA damage. These
mechanisms have been conserved from prokaryotes to eukaryotes, including
plants and post-mitotic organisms such as O. me/anogater and C. e/egans. The
ubiquitous nature of DNA damage tolerance pathways attests to their importance
in genome maintenance. The molecular details surrounding these pathways are
only now being elucidated, and the most intensively studied organisms are E. coli
amongst the prokaryotes and S. cerevisiae amongst the eukaryotes. The
increased complexity of damage tolerance pathways in higher eukaryotes, in
particular the presence of a number of polymerases that are not found in lower
organisms, has obscured the molecular mechanisms involved. Of particular
interest in this regard are the events surrounding the switch from replicative to Yfamily DNA polymerases and the factors that govern which of the universe of
pOlymerases is to be employed when the replicative complex is stalled at a
particular lesion. One notion in the literature supposes that polymerases are
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specialized for bypass of particular lesions. This arose from in vitro data using
purified polymerases in the absence of accessory proteins, such as PCNA.
These data indicate that pol eta bypasses T-T CPO with the preferential insertion
of A-A across form the lesion, thereby being error-free. Teleologically, this
specialization is supported by the fact that the UV component of sunlight is the
most ubiquitous carcinogen to which organisms are exposed, and T-T CPO are
the most common photoproduct. If true, then are other polymerases specialized
for other adducts, such as those induced by chemical carcinogens? It is difficult
to imagine how a stalled polymerase complex would differentiate between one
helix-distorting lesion and another. An alternative possibility, which is not
necessarily mutually exclusive with the lesion-specific idea, is that there is a
hierarchy of polymerases. My approach to begin to address the issue of the
events surrounding polymerase switching in higher eukaryotic cells was to
examine the mutagenic phenotype of cells derived from mice with combinatorial
deficiencies in pol eta and/or pol iota. Importantly, the development of these
mouse models allows us to examine the relationship between mutagenesis and
carcinogenesis in a detailed manner.
The discovery in 1999 of DNA polymerase eta and its deficiency as the
molecular defect underlying the skin cancer-prone XP variant syndrome was a
major development on the field of mutagenesis. This immediately led to an
intensive international effort to develop a knockout mouse. However, many
attempts to accomplish this resulted in embryonic lethality, a result that remains
puzzling even now since lethality does not accompany biallelic deficiency in
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human cells. Parenthetically, it is speculated that disruption of a large genomic
region surrounding the pol eta gene disrupts another gene required for
development. Fortunately, Dr. Kunkel and Dr. Kucherlapati were able to devise a
strategy to ablate the polymerase domain with minimal disruption to the genomic
structure surrounding the gene. The mutagenesis studies reported in this
dissertation were derived, in part, from these mice. I found that these cells
recapitulate the UV sensitivity of human XP variant cells to a remarkable extent.
For instance, the 0 37 of murine cells deficient in pol eta is - 3 J/m 2 , which
compares favorably with the reported value of 3.8 J/ m2 in XP variant cells. More
importantly, the murine cells are extraordinarily hypermutable with respect to UV.
The frequency of mutations at every UV fluence examined was several fold
higher than that observed in wild-type cells.

Further, examination of the

spectrum of mutations indicated that most of the mutations arose from putative
photoproducts in the leading strand template, and there was a very high
proportion of CG to AT transversions, all of which arose from this strand. This
spectrum is very similar to that found in XP variant cells, and confirm the
hypothesis that pol eta preferentially acts on the leading strand template. In its
absence, another, more error-prone enzyme assumes this function resulting in
hypermutability.
accelerated

Carcinogenesis studies with

UV-induced

skin

these

cancer phenotype,

as

mice

resulted

in

expected from

an
the

hypermutability of the cells derived from these mice and in accord with the
clinical observations in XP variant patients.
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In contrast to the phenotype of the pol eta-deficient mice, pol iota
deficiency resulted in greatly reduced mutant frequency compared to wild-type
cells. Examination of the mutation spectrum derived from these mice showed that
there were no differences in the kinds of mutations induced by UV, but the
frequency of mutations arising from photoproducts in the lagging strand template
was greatly reduced. The importance of these findings is that this is the first clear
demonstration that pol iota has a biological function, performing error-prone
bypass of UV photoproducts in vivo. Further, data support a model in which pol
eta primarily acts on the leading strand template at the same time that pol iota
acts on the lagging strand. The function of pol iota becomes even more apparent
when pol eta is also absent, as in the double knockout. In this case, the extreme
hypermutability resulting from the pol eta deficiency is reduced essentially to wild
type levels. The pol iota deficiency in this background reduces mutations arising
from photoproducts in both strands, but has a proportionally greater effect on
those in the lagging strand template. These data support the conclusion that pol
iota is the principal TLS polymerase in the absence of pol eta. Further, a third
polymerase is able to conduct mutagenic photoproduct bypass, since the mutant
frequency in the double knockout is reduced but not to zero.

It can be

speculated that this polymerase may be pol kappa, and suggests that the
preferred hierarchy is pol eta > pol iota > pol kappa, at least for UV
photoproducts.
There is a large body of data to support the hypothesis that cancer
results from the accumulation of mutations in critical growth-control genes.

115

Therefore, the greatly reduced frequency of mutations in the cells derived form
the double knockout mice would predict that these mice would develop skin
cancer with a much greater latency than the pol eta (XP variant) mice.
Unexpectedly, however, the former mice developed squamous cell skin cancer
with a greatly decreased latency, which was highly statistically significant. The
reasons for this are speculative and form the basis of future studies.
The simplest of explanations would be that mutagenesis at the Hprt locus in
primary fibroblasts does not reflect mutations in the cell types and/or genes most
relevant to development of skin tumors in mice. Opposition to this hypothesis is
supported by measurements of mutagenesis at the Hprt locus in pol eta-deficient
XP variant fibroblasts that do correlate with elevated susceptibility to skin cancer.
Despite this evidence, it would be possible to further test against Hprt criticism
through the isolation of keratinocytes, the cell type of tumor origin, and
comparatively sequence key genes such as p53 and check for mutation
spectrum differences.
Another possibility is that pol iota may play an important role in the
development of normal immunity, such that a deficiency in pol iota would
compromise immune suppression of skin cancer and lead to increased
susceptibility. This possibility is unlikely due to reports of normal class switch
recombination and somatic hypermutation of immunoglobulin genes in 129derived strains of mice, many substrains of which have a naturally occurring
deficiency of pol iota. However these studies were not completed during UVirradiation and may not rule out the possibility that difference in immune
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suppression may remain. Thus, inflammation may still playa large part in the
observed difference in tumor formation and would have to be tested as the
animals were being exposed to UV-light.
Another possibility, and the one I favor, is the idea that pol iota has
multiple cellular roles and modulates cancer susceptibility. One role that can be
experimentally tested is that pol iota is involved in cell cycle checkpoint
responses to DNA damage. For instance, it has been known for some time that
the mouse pol iota gene is on chromosome 18 and within the Par2 (pulmonary
adenoma resistance 2) locus. This is a major determinant of susceptibility to
urethane-induced pulmonary adenomas. A defective pol iota allele in the
129X 1ISv mouse strain has been shown to be associated with increased

susceptibility to urethane-induced lung tumors. The possibility of additional roles
for pol iota remains and is currently under active investigation.
In Chapter III the well-established TLS polymerase REV1 was targeted in
an attempt to lower the incidence of B[a]P induced murine lung tumors. These
studies were based on earlier observations from the McGregor laboratory that
ribozyme-mediated REV1 inhibition reduced BPDE-induced mutation in cell
culture. In these studies endogenous REV1 mRNA in the lung was effectively
lowered with the use of novel treatments. These treatments included the use of a
REV1 mRNA targeting hammerhead ribozyme by delivery through PEl mediated
aerosolized therapy. This reduction was found to effectively decrease the
multiplicity of B[a]P induced tumors in the murine lung. This reduction did not
affect the size or types of tumors induced suggesting that pure inhibition of
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cancer formation at the initiation step was attained and not just a progressive
delay. These studies support the use of targeting TLS as a chemoprotective
measure. The question remains as to why inhibiting certain TLS polymerase has
such a diverse impact on cancer formation as shown by the end result of cancer
formation.
The provocative question regarding TLS implications in cancer is
highlighted by comparisons between the end cancer results of Chapter II and III.
In Chapter II the tumors appeared faster with TLS polymerase inhibition but TLS
polymerase inhibition in Chapter III reduced tumor formation. The differences
between these studies are supportive evidence that for a true decrease in cancer
formation to occur TLS may have to be inhibited completely. If TLS is completely
inhibited, cells are forced to resolve blocked DNA replication forks either by errorfree recombination or to undergo apoptosis. If TLS inhibition occurs at only the
level of the specific polymerases responsible for bypass other polymerases may
assume the bypass. This bypass could occur in either an error-prone or errorfree manner presumably dependent on both the type of lesion and specific
polymerase performing the bypass. This mUlti-polymerase bypass is supported in
Chapter" with pol iota assuming a larger role on both the leading and lagging
strands in the absence of pol eta. Additionally, because there were residual
mutations in the double knockouts, at least one other polymerase is capable of
lesion bypass. This indicates TLS in Chapter II was not stopped but was rather
merely altered. In contrast, REV1 inhibition appears to reduce the incidence of
cancer. REV1 function in TLS is not considered to be catalytic, rather may be
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structural acting to tether all of the polymerases that actually perform the bypass.
Thus, REV1 inhibition abolishes TLS complex formation and drastically reduces
the ability of cells to insert nucleotides across from lesions through TLS. With
TLS completely shut down the logical system to assume function would be
damage avoidance pathways. This pathway would appear to assume the role of
TLS in an error free manner using undamaged templates to replicate the DNA.
These data suggest that the most clinically useful approach in chemoprevention
would be to shut down TLS completely, rather than attempting selective
polymerase inhibition.
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